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Abstract
A popular approach to projecting cancer absolute risk is to integrate a relative hazard function of predictors
with hazard rates obtained from different sources, where the relative hazard function is often approximated by
an odds ratio function. To assess added values of candidate risk predictors, it is very common that data for
standard risk predictors is fully available from a frequency-matched case-control study, but that of candidate
predictors is available only for a subset of cases and controls. In the first project, we developed statistical
measures for quantifying predictive accuracy of cancer absolute risk prediction models, accommodating
incomplete predictor variables. We particularly focused on a measure that is useful for evaluating efficiency of
model-based cancer screening, the proportion of cases that can be captured by screening only people with
high projected risk. In the second project, using a logistic regression model to describe the relationship
between cancer status and risk predictors, we developed a novel semiparametric maximum likelihood
approach that accommodates incomplete predictor data under rare disease approximation for the estimation
of odds ratio parameters and the distribution of candidate predictors. Through theoretical and simulation
studies, we showed that our estimator is consistent with an asymptotically normal distribution and has
improved statistical efficiency. In the third project, we applied the statistical methods developed in the first
two to evaluate the added values of percent mammographic density and breast cancer risk SNPs in breast
cancer absolute risk projection. Our results showed that the two sets of predictors had similar added values
and can lead to more efficient model-based screening for breast cancer. In the fourth project, we applied the
semiparametric maximum likelihood method to a family-supplemented study design that we proposed to
address survival bias in case-control genetic association studies.
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ABSTRACT
CANCER ABSOLUTE RISK PROJECTION WITH INCOMPLETE PREDICTOR
VARIABLES
Lu Chen
Jinbo Chen
A popular approach to projecting cancer absolute risk is to integrate a relative hazard
function of predictors with hazard rates obtained from different sources, where the
relative hazard function is often approximated by an odds ratio function. To assess
added values of candidate risk predictors, it is very common that data for standard
risk predictors is fully available from a frequency-matched case-control study, but that
of candidate predictors is available only for a subset of cases and controls. In the first
project, we developed statistical measures for quantifying predictive accuracy of can-
cer absolute risk prediction models, accommodating incomplete predictor variables.
We particularly focused on a measure that is useful for evaluating efficiency of model-
based cancer screening, the proportion of cases that can be captured by screening
only people with high projected risk. In the second project, using a logistic regres-
sion model to describe the relationship between cancer status and risk predictors, we
developed a novel semiparametric maximum likelihood approach that accommodates
incomplete predictor data under rare disease approximation for the estimation of odds
ratio parameters and the distribution of candidate predictors. Through theoretical
and simulation studies, we showed that our estimator is consistent with an asymptot-
ically normal distribution and has improved statistical efficiency. In the third project,
we applied the statistical methods developed in the first two to evaluate the added
iv
values of percent mammographic density and breast cancer risk SNPs in breast can-
cer absolute risk projection. Our results showed that the two sets of predictors had
similar added values and can lead to more efficient model-based screening for breast
cancer. In the fourth project, we applied the semiparametric maximum likelihood
method to a family-supplemented study design that we proposed to address survival
bias in case-control genetic association studies.
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CHAPTER 1
Introduction
1
1.1.
Cancer absolute risk is the probability that an individual will develop cancer in a
certain age interval without dying from competing causes. Its computation involves
the relative hazard function, the age specific baseline hazard, and age specific com-
peting risk hazard. The relative hazard function can be approximated by the odds
ratio (OR) function of the predictors since cancer outcomes are rare. The baseline
hazard rates can be calculated from composite hazard rates available from population
databases such as the Surveillance, Epidemiology, and End Results (SEER) program
when coupled with the OR function and distribution of risk predictors. The hazard
rates of mortality can be obtained from the National Death Index. This composite
approach to cancer absolute risk projection was first used by Gail et al. (1989) to
develop the breast cancer risk assessment tool (BCRAT), commonly referred to as
the ”Gail model”. The BCRAT is the current National Cancer Institute (NCI) stan-
dard for predicting breast cancer absolute risk. It has been widely used for designing
clinical trials and counseling individual woman. It can also be usefulness for selecting
high-risk women to engage in breast cancer screening programs (Saslow et al., 2007).
The BCRAT includes four risk predictors, age at menarche (Agemen), age at first
live birth (Ageflb), number of previous breast biopsies (Bbiops), and number of first-
degree relatives (Numrel) (mother/sisters) who have had breast cancer (Gail et al.,
1989). It calibrates well but only has a modest discriminatory accuracy with area
under the ROC curve (AUC) ranging from 0.58 to 0.64 (Costantino et al., 1999;
Freedman et al., 2005; Rockhill et al., 2001). Therefore, it has been of great in-
terest to increase the predictive accuracy of the BCRAT by incorporating emerging
risk predictors. Percent mammographic density (PD), which is a measure of breast
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density as the percent of dense area on the mammogram image, has recently been
established as one of the strongest risk predictors for breast cancer (Byrne et al.,
1995; Tice et al., 2008). Chen et al. (2006) and Chen et al. (2008) developed an
OR function and corresponding absolute risk prediction model that includes PD as
a new predictor, and found that it led to a modest increase in the AUC statistic.
Breast cancer risk associated SNPs, independently or in combination with PD, have
recently been extensively evaluated for their added values in improving breast cancer
risk prediction. A Swedish study showed that adding PD, body mass index, and
18 breast cancer risk SNPs can improve the AUC of a Swedish-Gail risk prediction
model from 0.55 to 0.62 (Darabi et al., 2012a). A theoretical study conducted in
the United Kingdom population showed that a 76-locus polygenetic risk score can
lead to improved risk stratification and added value more than a clinical measure of
breast density, the BI-RADS (Garcia-Closas, Gunsoy, and Chatterjee, 2014). In the
Breast Cancer Surveillance Consortium (BCSC) risk prediction model, the 76-locus
polygenetic risk score was shown to predict independently of BI-RADS breast density
(Vachon et al., 2015). It improved the BCSC model that includes BI-RADS breast
density as a predictor, increasing AUC from 0.66 to 0.69 and improving classification
of the high-risk women. To date, the combined value of PD and the 76 breast cancer
risk SNPs for improving the accuracy of the BCRAT has not been evaluated.
Notably, the evaluation of the BCRAT and other models has largely been based on
the AUC statistic, which has been argued to be of limited relevance for clinical ap-
plications. Alternative measures of predictive accuracy have been proposed, such as
predictive curves (Gail and Pfeiffer, 2005; Gu and Pepe, 2009; Pepe, Gu, and Morris,
2010; Pepe et al., 2008), the proportion of cases followed (PCF) and the proportion
needed to follow up (PNF) (Pfeiffer and Gail, 2011). But these measures were de-
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signed for binary outcomes and are not directly applicable for evaluating absolute risk
models that were developed using the composite approach described above. In Chap-
ter 2, we adapt several existing predictive accuracy statistics to accommodate the
composite approach to absolute risk prediction, and fully evaluate the added value of
PD and/or breast cancer risk SNPs using the adapted measures, including AUC, posi-
tive predictive values(PPV), and PCF/PNF. For the BCRAT risk predictors and PD,
we use data from the Breast Cancer Detection and Demonstration Project (BCDDP).
BCDDP started in 1973 and was originally designed to assess whether mammographic
screening can reduce morbidity and mortality of breast cancer. It recruited 243,221
white women from 1973 to 1975 and followed each woman for at least 5 years. A
age-stratified case-control study was conducted in 1979, and the BCRAT risk predic-
tors were available for all 2,808 cases and 3,119 controls. But only 1,217 cases and
1,616 controls had PD measurements available. SNP genotype data is not available
from the BCDDP. Therefore, it is necessary to utilize estimates of OR parameters
and minor allele frequencies from the literature. Our proposed method of estimating
adapted accuracy statistics can accommodate these additional complications.
1.2.
The challenge of incomplete predictor data as in the BCDDP in the development
of absolute risk prediction models is widespread. For example, it may require up-
to-date high technology to measure emerging risk factors, which may be too expen-
sive or technically infeasible to use on all subjects. One such example is estrogen
metabolomic measurements. It may also be possible that genotype data cannot be
made available for all subjects. When standard risk predictors are available from
a stratified/frequency-matched case-control study but candidate predictors are only
collected on a subset, the data can be viewed as being collected from a two-phase
4
stratified case-control design. In phase I, the case-control status and standard risk
predictors are collected on all cases and controls. In phase II, the costly predictor is
measured on a subset selected based on case-control status and phase I variables. The
incomplete data conforms to a missing at random mechanism (Little and Rubin, 1987)
because the missingness happened by study design. The development of statistical
methods for analysis has been focused on integrated analysis of phase I and phase
II data to achieve increased precision for estimating OR parameters that quantify
association between the binary outcome and risk variables (Breslow and Cain, 1988;
Breslow and Chatterjee, 1999; Breslow and Holubkov, 1997; Chen et al., 2008; Scott
and Wild, 1997). In particular, Chen et al. (2006) and Chen et al. (2008) proposed
a pseudo-likelihood approach to analyzing the two-phase stratified case-control data.
This approach was applied to analyze the BCDDP data in Chapter 2.
We are interested in developing a more efficient approach to estimating cancer ab-
solute risk, which requires efficient estimation of both OR parameters and the joint
distribution of both the standard and candidate predictors given age. Usually the
distribution of standard risk predictors can be obtained from national population
databases, which is preferable to assure the applicability of the model to the general
population. But the candidate predictor is often not included in these databases.
Therefore, our goal of efficient estimation involves that of the OR parameters and the
conditional distribution of the new predictor given standard predictors and match-
ing variables. The latter has to be estimated separately from phase II controls if
the pseudo-likelihood approach (Chen et al., 2006) is adopted for estimating the OR
parameters. In Chapter 3, we proposed a semiparametric maximum likelihood esti-
mation approach to jointly estimating the distribution of the new predictor and the
OR parameters using data from both phase I and phase II subjects. In addition,
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Chen et al. (2006) studied the large sample approximation of the distribution of their
proposed pseudo-likelihood estimator (Chen et al., 2006), but they did not assess the
finite sample performance nor the accuracy of the large sample approximation of the
distribution. Through extensive simulation studies and application to the analysis of
the BCDDP data, we fully evaluate the finite sample performance of our new and the
pseudo-likelihood estimators. In particular, we evaluate the corresponding efficiency
gain for estimating model parameters as well as statistics for quantifying predictive
accuracy when these approaches are used in the development of the BCRAT that
incorporates PD.
1.3.
In Chapter 4, we apply the adapted predictive measures developed in Chapter 2
to assess the incremental values of PD and 76 breast cancer risk associated SNPs
discovered to date for improving the breast cancer risk assessment tool (BCRAT)
Gail et al. (1989) for risk stratification, and thereby assess their potential in improving
model-based breast cancer screening in the United States female population. PD is
now automatically provided by most breast imaging process software. Incorporation
of PD into the BCRAT was found to lead to a modest increase in AUC Chen et al.
(2008). A small number of genetic susceptible variants for breast cancer Gail (2008);
Wacholder et al. (2010) were found to lead to a smaller increase in AUC than the PD.
But no data is available yet for quantifying the combined values of PD and breast
cancer risk SNPs in improving risk stratification in the U.S. female population. The
U.S. Preventive Task Force recommended not to routinely screen women aged 40∼49
years, which has been heavily debated by the radiology society. Therefore, we also
calculate the percentage of women in the United States aged 40∼49 years whose
breast cancer risk is higher than the risk threshold for chemoprevention (3%).
6
1.4.
In Chapter 5, we apply the semi-parametric maximum likelihood method developed in
Chapter 2 to address the issue of survival bias in genetic association studies. Survival
bias is difficult to detect and adjust for in case-control genetic association studies
but can invalidate findings when only surviving cases are studied and survival is
associated with the genetic variants under study. We propose a design where one
genotypes genetically-informative family members (such as offspring, parents, and
spouses) of deceased cases and incorporates that surrogate genetic information into
a retrospective maximum likelihood analysis. We show that inclusion of genotype
data from first-degree relatives permits unbiased estimation of genotype association
parameters. We derive closed-form maximum likelihood estimates for association
parameters under the widely used log-additive and dominant association models.
Our proposed design not only permits a valid analysis but also enhances statistical
power by augmenting the sample with indirectly studied individuals. Gene variants
associated with poor prognosis can also be identified under this design. We provide
simulation results to assess performance of the methods.
7
CHAPTER 2
Quantifying Predictive Accuracy of Cancer Absolute
Risk Prediction Models
8
2.1. Introduction
Cancer absolute risk is the probability that an individual will develop cancer in a
certain age period without dying from competing causes. Its computation involves
the relative hazard function, the age specific baseline hazard, and age specific com-
peting risk hazard. The relative hazard function can be approximated by the odds
ratio (OR) function of the predictors since cancer outcomes are rare. The baseline
hazard rates can be calculated from composite hazard rates available from population
databases such as the Surveillance, Epidemiology, and End Results (SEER) program
when coupled with the OR function and distribution of risk predictors. The hazard
rates of mortality can be obtained from the National Death Index. This composite
approach to cancer risk projection was used by Gail et al., 1989 to develop the breast
cancer risk assessment tool (BCRAT), commonly referred to as the ”Gail model”.
The BCRAT is the current National Cancer Institute (NCI) standard for predicting
breast cancer absolute risk. It has been widely used for designing clinical trials and
counselling individual woman. It has recently also been evaluated for its usefulness
in designing model-based breast cancer screening program.
The BCRAT uses four risk predictors, age at menarche (Agemen), age at first live
birth (Ageflb), number of previous breast biopsies (Nbiops), and number of first-
degree relatives (Numrel) (mother/sisters) who have had breast cancer. It calibrates
well but only has a modest discriminatory accuracy with area under the ROC curve
(AUC) ranging from 0.58 to 0.64 (Costantino et al., 1999; Freedman et al., 2005;
Rockhill et al., 2001). Therefore, it has been of great interest to increase the pre-
dictive accuracy of the BCRAT by incorporating emerging risk predictors. Percent
mammographic density (PD), which is a measure of breast density as the percent of
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dense area on the mammogram image, has been established to be one of the strongest
risk predictors for breast cancer. Chen et al., 2006 and Chen et al., 2008 developed
an OR function and corresponding absolute risk prediction model that includes PD
as a new predictor, and found that it led to a modest increase in the AUC statis-
tic. Breast cancer risk associated SNPs, independently or combined with PD, have
recently been extensively evaluated for their added values in improving breast cancer
risk prediction. A Swedish study showed that adding PD, body mass index, and 18
breast cancer risk SNPs can improve the AUC of a Swedish-Gail risk prediction model
from 0.55 to 0.62. A theoretical study conducted in the United Kingdom population
showed that a 76-locus polygenetic risk score can lead to improved risk stratification
and added more than a clinical measure of breast density, the BI-RADS. In the Breast
Cancer Surveillance Consortium (BCSC) risk prediction model, the 76-locus polyge-
netic risk score was shown to predict independently of BI-RADS breast density. It
improved the BCSC model that also includes BI-RADS breast density as a predictor,
increasing AUC from 0.66 to 0.69 and classification of the high-risk women. But to
date, the combined value of PD and the 76 breast cancer risk SNPs for improving the
accuracy of the BCRAT has not been evaluated.
Notably, the evaluation of the BCRAT and other models has largely been based
on the AUC statistic, which has been argued to be of little relevance for clinical
applications. Alternative measures of predictive accuracy have been proposed, such as
several variants of predictive curves (Gail and Pfeiffer, 2005; Gu and Pepe, 2009; Pepe,
Gu, and Morris, 2010; Pepe et al., 2008), the proportion of cases followed (PCF) and
the proportion needed to follow up (PNF) (Pfeiffer and Gail, 2011). These measures
were designed for binary outcomes and have been adapted to time-to-event outcomes,
but they are not directly applicable for evaluating absolute risk models that were
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developed using the composite approach described above. In this chapter, we adapt
several existing predictive accuracy statistics to accommodate the composite approach
to absolute risk prediction, and evaluate the added value of PD and/or breast cancer
SNPs using the adapted measures, including AUC, positive predictive values(PPV),
and PCF/PNF. For the BCRAT risk predictors and PD, we used data from the
Breast Cancer Detection and Demonstration Project (BCDDP). BCDDP started in
1973 and was originally designed to assess whether mammographic screening can
reduce morbidity and mortality of breast cancer. It recruited 243,221 white women
in 1973 to 1975 and followed each womant for at least 5 years. An age-stratified case-
control study was conducted in 1979, and the BCRAT risk predictors were available
for all 2808 cases and 3119 controls. But only 1217 cases and 1616 controls had PD
measurements available.
We view the BCDDP data as collected from a two-phase age-stratified/frequency-
matched case-control design as in Chen et al., 2006. In phase I, the case-control
status and standard BCRAT risk predictors were collected on all cases and controls.
In phase II, PD was measured on a subset selected based on case-control status and
phase I variables. The incomplete data conforms to a missing at random mechanism
(Chen et al., 2008; Little and Rubin, 1987). To address this problem, Chen et al.
(2008) developed a pseudo-likelihood approach to deriving an OR function for breast
cancer from the BCDDP age-stratified case-control data that incorporated PD, which
we use in the absolute risk calculation in this chapter. Our estimators of adaptive
predictive accuracy statistics naturally accommodate the incomplete predictor data.
In addition, SNP genotype data is not available in the BCDDP. Therefore, it was
necessary to utilize estimates of OR parameters and minor allele frequencies from
the literature. To include the SNP predictors into the absolute risk prediction, we
11
assumed that the effects of SNPs and other non-genetic risk predictors were additive
on the logistic scale, that the OR parameters for SNPs were the same as those available
from the literature, and that the OR parameters for non-genetic risk predictors were
the same as those estimated from the BCDDP. Our proposed method of estimating
adapted accuracy statistics can accommodate these additional complications.
2.2. Methods
2.2.1. Adapted statistics for quantifying predictive accuracy of absolute risk prediction
models
Let Q denote the collection of predictors in the relative hazard function, β denote
hazard ratio parameters, λ−β denote the other Euclidean parameters that are involved
in the absolute risk prediction, and λ denote the collection of all parameters, λ=(β,
λ−β). Further, let h1(t;λ) and h2(t) denote baseline hazard rates of cancer and
competing risk hazard at age t, respectively. Then the absolute risk Ψ(Q, t0, τ ;λ) in
the age interval (t0, t0+τ) can be calculated using the standard formula for cumulative
incidence function:
Ψ(Q, t0, τ ;λ) =
∫ t0+τ
t0
h1(u;λ)r(Q;β) exp
[
−
∫ u
t0
{h1(v;λ)r(Q;β) + h2(v)} dv
]
du,
where r(Q;β) is equal to eQβ and can be approximated by the OR function eQβ/1 + eQβ
for rare cancer outcomes. Ideally, a cohort can be assembled from the target popu-
lation where the risk prediction model is intended to be applied to, from which all
parameters involved in Ψ(Q, t0, τ ;λ) can be estimated. But this is rarely the case.
In fact, the first version of the BCRAT Gail et al. (1989) was developed based on
the BCDDP cohort. Latter, it was found that it did not calibrate well because the
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baseline hazard rates of breast cancer in BCDDP was higher than those in the gen-
eral U.S. female population. Therefore, for developing cancer absolute risk prediction
models, it has been popular to derive baseline hazard rates h1(t;λ) from compos-
ite hazard rates reported in population databases such as SEER. Let h∗1(t) denote
age-specific composite hazard rates and pλ−β(Q|t) the probability distribution of pre-
dictors Q at age t indexed by parameters λ−β. Then h1(t;λ) can be calculated as
h1(t;λ) = h
∗
1(t){1 − AR(t;λ)}, where AR(t;λ) is the attributable risk for r(Q;β)
and calculated as
AR(t;λ) = 1− 1/
∑
Q
pλ−β(Q|t)r(Q;β).
The competing risk hazard rates h2(t) can be obtained from population databases
such as the National Death Index. Define risk score Ut0(Q;β) = log{r(Q;β)} with
Q values measured at age t0. Ψ(Q, t0, τ,λ) is an increasing function of Ut0(Q;β) for
a given t0 and τ . Hereafter we write Ψ(Q, t0, τ ;λ) as Ψt0,τ (Ut0 ;λ). The cumulative
distribution function of Ut0 , denoted as F (Ut0 ;λ), can be estimated as Fˆ (Ut0 ; λˆ) =∑
Q I
[
Qβˆ ≤ Ut0
]
pˆλ̂−β(Q|t0), which is needed in the estimation of all the proposed
statistics below. Let f(Ut0 ;λ) denote the probability density function of Ut0 and its
estimate as fˆ(Ut0 ;λ).
To assess the added values of breast cancer risk SNPs for improving breast cancer risk
prediction, SNP genotype data may be unavailable in studies that provide data for
non-genetic risk predictors. A compromise approach has been widely adopted that
uses OR estimates and minor allele frequencies from the literature (Gail and Pfeiffer,
2005; Gail et al., 1989). Under the assumptions that genetic and non-genetic risk
predictors are independently distributed and that their effects on breast cancer risk are
additive on the logistic scale, SNP genotypes have been incorporated into the absolute
risk prediction and evaluated for their incremental values. Our simulation studies
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as shown in Section 2.3 below supported this practice: estimates of the predictive
accuracy statistics are usually reasonable approximations to those when joint analysis
of SNP genotype and non-genetic risk predictor data is plausible although are a little
conservative. Therefore, this compromise approach can be useful to assess added
values for other emerging risk predictors. Suppose that there are l external predictors
of interest. Let W = (W1,W2, ...,Wl) denote the vector of the external predictors and
βw the corresponding log OR vector. Now the OR vector becomes (β,βw) and Q is
expanded to include W as well. Then the absolute risk is calculated using the same
formula as above, but in the calculation of attributable risk AR(t;λ),
∑
Q,W
r(Q,W ;β)pλ−β(Q,W | u) =
{∑
Q
eQβp(Q|u)
}
l∏
j=1
∑
Wj
e
Wjβwj p(Wj)
 .
Adapted AUC and PPV statistic Let ψ be a pre-specified cutoff value for the
absolute risk Ψt0,τ (Ut0 ;λ), and T denote age at cancer diagnosis. We extend the
true positive rate (TPR) to the setting of absolute risk as the probability that an
individual who develops cancer in the age interval (t0, t0 + τ), i.e. t0 < T ≤ t0 + τ , is
classified as high risk at t0 by the criteria Ψt0,τ ≥ ψ,
TPRψ(t0, τ ;λ) = p [Ψt0,τ (Ut0 ;λ) ≥ ψ|t0 < T ≤ t0 + τ ] .
Similarly, We define the false positive rate (FPR) as the probability that an individual
who remains cancer-free by age t0 + τ , i.e. T > t0 + τ , is classified as high risk,
FPRψ(t0, τ ;λ) = p [Ψt0,τ (Ut0 ;λ) ≥ ψ|T > t0 + τ ] .
We extend the the area under the ROC curve (AUC) correspondingly as
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TPRFPR−1(t0,τ ;λ)(t0, τ ;λ).
We propose a model-based approach to the estimation of the adapted AUC statistic.
To estimate TPR, we re-write it using the Bayes rule
TPRψ(t0, τ ;λ) =
p [Ψt0,τ (Ut0 ;λ) ≥ ψ, t0 < T ≤ t0 + τ ]
p (t0 < T ≤ t0 + τ)
=
∑
Ut0
I [Ψt0,τ (Ut0 ;λ) ≥ ψ] p [Ut0 , t0 < T ≤ t0 + τ ]∑
Ut0
p [Ut0 , t0 < T ≤ t0 + τ ]
=
∑
Ut0
I [Ψt0,τ (Ut0 ;λ) ≥ ψ] p [t0 < T ≤ t0 + τ |Ut0 ] p(Ut0)∑
Ut0
p [t0 < T ≤ t0 + τ |U ] p(Ut0)
=
∑
Ut0
I [Ψt0,τ (Ut0 ;λ) ≥ ψ] Ψt0,τ (Ut0 ;λ)f(Ut0 ;λ)∑
Ut0
Ψt0,τ (Ut0 ;λ)f(Ut0 ;λ)
.
Then TPR can be estimated as
T̂PRψ(t0, τ ;λ) =
∑
Ut0
I
[
Ψt0,τ (Ut0 ; λˆ) ≥ ψ
]
Ψt0,τ (Ut0 ; λˆ)fˆ(Ut0 ; λˆ)∑
Ut0
Ψt0,τ (Ut0 ; λˆ)fˆ(Ut0 ; λˆ)
.
Similarly, FPR can be estimated as
F̂PRψ(t0, τ ;λ) =
∑
Ut0
I
[
Ψt0,τ (Ut0 ; λˆ) ≥ ψ
] [
1−Ψt0,τ (Ut0 ; λˆ)
]
fˆ(Ut0 ; λˆ)∑
Ut0
[
1−Ψt0,τ (Ut0 ; λˆ)
]
fˆ(Ut0 ; λˆ)
.
Then the AUC statistic can be estimated as T̂PR
F̂PR
−1
(t0,τ ;λˆ)
(t0, τ ; λˆ).
Similar as TPR, we define PPV as the probability that an individual whose absolute
risk at age t0 is above threshold ψ, Ψt0,τ ≥ ψ, will develop cancer in the age interval
(t0, t0 + τ):
PPVψ(t0, τ ;λ) = p [t0 < T ≤ t0 + τ |Ψt0,τ (Ut0 ;λ) ≥ ψ] .
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Similar as the estimation of TPR/FPR above, we propose a model-based estimator
as
P̂PVψ(t0, τ ; λˆ) =
∑
Ut0
I
[
Ψt0,τ (Ut0 ; λˆ) ≥ ψ
]
Ψt0,τ (Ut0 ; λˆ)fˆ(Ut0 ; λˆ)∑
Ut0
I
[
Ψt0,τ (Ut0 ; λˆ) ≥ ψ
]
fˆ(Ut0 ; λˆ)
.
Adapt the PCF/PNF statistics to the absolute risk projection PCF at percentage
q, written as PCF(q), is defined as the proportion of individuals who develop cancer
in age interval (t0, t0 + τ) among those whose absolute risk exceeds the (1 − q)th
percentile in the target population. PNF at percentage p is defined as the proportion
of the population at highest risk that is needed to be followed so that a proportion p
of those destined to develop cancer in the age interval (t0, t0 +τ) will be captured. Let
G(ψ;λ) denote the cumulative distribution function of the absolute risk Ψt0,τ (Ut0 ;λ),
G(ψ;λ) = p [Ψt0,τ (Ut0 ;λ) ≤ ψ] =
∑
Ut0
I [Ψt0,τ (Ut0 ;λ) ≤ ψ] f(Ut0 ;λ).
We estimate PCF(q) as P̂CF(q; λˆ):
P̂CF(q; λˆ) =
∑
Ut0
I
[
Ψt0,τ (Ut0 ; λˆ) ≥ G−1(1− q)
]
Ψt0,τ (Ut0 ; λˆ)fˆ(Ut0 ; λˆ)∑
Ut0
Ψt0,τ (Ut0 ; λˆ)fˆ(Ut0 ; λˆ)
By definition, PNF is the inverse function of PCF. That is,
p
{
Ψt0,τ (Ut0 ;λ) ≥ G−1 [1− PNF(p)] |t0 ≤ T ≤ t0 + τ
}
= p.
Therefore, PNF can be estimated by inverting the PCF estimate P̂CF(q; λˆ).
Large sample distribution of the adpated statistics Let PAS(λ) denote any of
the four predictive accuracy statistics, where “PAS” stands for “predictive accuracy
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statistics”. The estimators that we proposed above can all be written as PAS(λˆ)
, where λˆ is consistent estimators of λ. Assume that λˆ is asymptotically normally
distributed with mean λ and variance Σλ. Based on Taylor series expansion, we can
show that P̂AS ∼ N (PAS,Σ).
Here the variance of PAS is estimated by Σˆ, which is derived using Talor series
expansion. Thus
Σˆ =
[
∂PAS(λˆ)
∂λ
]
Σˆλ
[
∂PAS(λˆ)
∂λ
]
,
where Σˆλ is consistent estimator for Σλ. We provide the theoretical asymptotic results
in the Appendix.
We present as follows the forms for ∂TPR(λˆ)
∂λ
as examples for ∂PAS(λˆ)
∂λ
. The other ex-
pressions of the first derivatives over λ and fU can be derived similarly.
∂T̂PRψ(t0, τ ; λˆ)
∂λ
=
∑
U
[
∂Iˆ
∂λ
Ψˆfˆ + Iˆ ∂Ψˆ
∂λ
fˆ + IˆΨˆ ∂fˆ
∂λ
]
∑
U Ψˆfˆ
−
[∑
U IˆΨˆfˆ
]{∑
U
[
∂Ψˆ
∂λ
fˆ + Ψˆ ∂fˆ
∂λ
]}
[∑
U Ψˆfˆ
]2
where Iˆ, Ψˆ and fˆ are the estimated indicator function, absolute risk function and joint
distribution of the predictors involved in the formulas of TPR. Number of predictors
in the cancer absolute risk prediction model can be very large since the distribution
of predictors given age can be estimated empirically. The dimension of Var
(
λˆ
)
will
be very high (probably as large as several hundreds), which makes the estimation of
the variance difficult. Therefore in practice, we calculate the variance of each statistic
by bootstrapping the original data set.
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2.2.2. Estimation of parameters λ with two-phase stratified case-control data
Motivated by the BCDDP, we consider that the relative risk/OR parameters β are
estimated from two-phase stratified case-control data, where one or more predictors
in Q are observed only in a selected subset of cases and controls. Chen et al. (2006)
proposed a general pseudo-likelihood (PL) approach to estimation, which we adopt
in the estimation of absolute risk and statistics PAS{λ, f(Ut0 ;λ)}. The PL method
stratified on standard risk factors and the matching variable. However, the data would
be too sparse after stratification. Methods for analyzing two-phase case-control data
(Breslow and Chatterjee, 1999; Breslow and Holubkov, 1997) are applicable to the
analysis of two-phase stratified case-control data. These methods utilize data on fully
observed predictors and thereby improve the efficiency of estimating OR parameters
through post stratification. But the consistency of these methods require stratification
on the sampling variables when applied to two-phase stratified case-control data.
This leaves little room for post-stratifying on the fully observed predictors, because
reasonable stratum sizes (rule of thumb is greater than 5) are necessary to ensure
finite sample performance. Recognizing that OR parameters for sampling variables
are not of interest, PL ignored phase I sampling variables and post-stratified only on
fully observed risk predictors.
Let Y denote the case-control status, A denote the matching variable, and X denote
risk predictors. Data on X is collected for n1 cases and n0 controls who are matched
on A, which is discrete and takes a small number of values. Let Z denote a single
predictor that is collected only on a subset of m1 cases and m0 controls (m1 ≤ n1,
m0 ≤ n0). Often, auxiliary information for Z is available in phase I which can be
exploited to increase efficiency for estimating the OR parameter for Z. For example,
weight is strongly correlated with PD and therefore is a useful auxiliary variable for
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PD. These auxiliary variables can be included in predictors X. The case-control
status Y is related to Q = (X,Z) via a logistic regression model
logitp(Y = 1||Q,A) = αa + βTQ, (2.1)
where αa is the sampling-stratum specific intercept parameter. The PL method for
estimating OR parameters β requires that the number of subjects with outcome
Y = y within each matching stratum A = a, Nya, in the cohort from which cases
and controls were assembled is known. Let nya denote such number in the case-
control study. Further, let K(X) denote a coarsened version of X for defining post-
stratification strata, which can be X itself when X is discrete with a small number
of levels. The PL method treated the stratified case-control sample as prospective
that conforms to the logistic regression model (2.1) but with a modified intercept to
adjust for case-control sampling
p∗(Y = y|X,Z,A) = exp
{
y
(
α∗a + β
T
xX + βzZ
)}
1 + exp {(α∗a + βTxX + βzZ)}
,
where α∗a = αa + log (n1aN0a/n0aN1a). The PL takes the form of the standard like-
lihood for the two-phase design with phase I data generated prospectively from the
modified model p∗(Y = y|X,Z,A), and the logarithm of which was given as
`PL =
m1+m0∑
i=1
log {p∗(Yi|Xi, Zi, Ai)p∗[Xi, Zi, Ai|K(Xi)]}+
n1∑
i=m1+1
log {p∗(Yi|K(Xi))}
=
m1+m0∑
i=1
log {p∗(Yi|Xi, Zi, Ai)p∗(Xi, Zi, Ai|K(Xi))}
+
n1∑
i=m1+1
log
{∫
Z
p∗(Yi|Xi, Z, Ai)p∗[Xi, Z, Ai|K(Xi)]dZ
}
.
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`PL is a log pseudo-likelihood but not a genuine likelihood because p
∗(Y = y|X,Z,A)
is not a real probability density function. Chen et al. (2008) showed that maximizing
`PL yields a consistent estimate of β and studied large sample properties of the
estimator βˆ.
Estimation of absolute risk and PAS also requires estimation of parameters in the
risk predictor distribution p(Q). Under the two-phase stratified case-control design,
one can appropriately model the conditional distribution pθ(Q|A), where θ is the
associated parameter vector, and estimate model parameters θ using data from phase
II controls. When the distribution for the matching variable A can be obtained from
external resources, p(Q) can be obtained as p(Q) =
∑
A pθ(Q|A)p(A).
2.3. The analysis of BCDDP data
We applied the developed methods to compare the predictive accuracy of four mod-
els for breast cancer absolute risk: BCRAT, BCRAT plus breast cancer risk SNPs,
BCRAT plus PD and weight, and BCRAT plus breast cancer risk SNPs, PD, and
weight. The ORs in the third model and those for non-genetic risk predictors in the
forth model were estimated by applying the PL method to the BCDDP data. Previ-
ous work used BMI rather than weight when modeling PD on breast cancer risk to
recognize the strong confounding effect of BMI. But only weight was available from
the BCDDP. We used 74 SNPs instead of 76 as in previous work because two of the
SNPs were not statistically significant in a recent meta analysis. The PL method
efficiently used data on variables Agemen, Nbiops, Ageflb, Numrel, and Weight that
was available on all cases and controls and accommodated the incomplete PD data.
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2.3.1. Absolute risk estimation and predictive accuracy statistics with the BCDDP
data and external SNP predictors
We describe the detailed methods for developing and evaluating the three variant
BCRAT models above. Denote the four standard predictors and weight as X =
(X1, X2, X3, X4, X5), PD as Z, so that Q = (X,Z), and the external 74 breast cancer
risk SNPs as W = (W1,W2, ...,W74). The controls were frequency-matched to cases
on age, A, in 5-year intervals, so that the sampling variable A here agrees with t0 in the
absolute risk formula in section 2.2.1. Therefore, the predictor distribution given age
u in section 2.2.1, pλ−β(Q|u), and the predictor distribution given matching variable
A in section 2.2.2, pθ(Q|A) concide. Below we express this distribution by pθ(Q|A).
We used the same numerical coding for (X1, X2, X3, X4, A) as in the BCRAT and
in Chen et al. (2008), and each component of W were coded as 0, 1, or 2 for the
minor allele count. We coded Z slightly different, however. Previous work categorized
PD into quartiles where the first quartile [0, 0.25) includes value 0. However, Z = 0
may indicate a genuine zero dense area but more likely suggests that a woman’s
dense area on the mammographic image was below the detection limit. Therefore,
we treated Z = 0 as a separate category resulting in 5 categories of PD. Denote the
corresponding categorized Z as Zc. The joint distribution of the predictors given
A, p(Q,W |A), which can be factorized as pθ(Zc|X,A)p(X|A)p(W ). Similar as the
BCRAT, we estimated p(X|A) non-parametrically from the National Health Interview
Survey (NHIS). We approximated pθ(Z
c|X,A) by the same distribution in controls,
pθ(Z
c|X,A;Y = 0). We model the continuous PD measure Z by a zero-inflated beta
regression model pθ(Z|X,A;Y = 0), so that pθ(Zc|X,A) =
∫
Ωc
pθ(Z|X,A;Y = 0) dZ,
where Ωc is the support for Z
c. In addition, the 74 breast cancer risk SNPs were
assumed to be independently distributed and each conforming to Hardy-Weinberg
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Equilibrium law, so that p(W ) =
∏74
j=1 p(Wj), p(Wj = 0) = (1− pwj)2, p(Wj = 1) =
2pwj(1− pwj), p(Wj = 2) = p2wj , E [Wj] = 2pwj , and Var [Wj] = 2pwj
(
1− pwj
)
.
The calculation of absolute risk involves the OR parameter estimates and the distri-
bution of the risk predictors. Instead of doing integration as shown in the absolute
risk formula, we sum over the age interval (A,A + τ) by treating the age variable A
as discrete numbers (e.g., 21, 22, 23, ...). However, A remains to be continuous in the
computation of pθ(Z
c|X,A;Y = 0).
The estimation of the distribution of UA = Qβ + Wβw, f(UA;λ), which is needed
in the calculation of all the predictive accuracy statistics, requires enumeration of all
possible combined values of (Q,W ) = (X,Zc,W ). But this is infeasible because of
the large number of SNPs. Therefore, instead of obtaining the exact distribution of
(Q,W ) at age A, we used the large sample approximation by resorting to the Central
Limit Theorem, so that UA is asymptotically normally distributed with mean and
variance
E[UA] = E [Xβx + Z
cβz | A] + E [Wβw | A]
=
∑
X,Zc
(Xβx + Z
cβz)
[∫
Ωc
pθ(Z | X,A;Y = 0)dZ
]
p(X | A) +
74∑
j=1
βwjE [Wj] ,
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and
Var[UA] = Var [Xβx + Z
cβz | A] + Var [Wβw | A]
= E
[
(Xβx + Z
cβz)
2 | A]− E2 [Xβx + Zcβz | A] + 74∑
j=1
Var
[
βwjWj
]
=
∑
X,Zc
(Xβx + Z
cβz)
2
[∫
Ωc
pθ(Z | X,A;Y = 0)dZ
]
p(X | A)
−
{∑
X,Zc
(Xβx + Z
cβz)
[∫
Ωc
pθ(Z | X,A;Y = 0)dZ
]
p(X | A)
}2
+
74∑
j=1
β2wjVar [Wj] .
With the resultant asymptotic distribution f(UA;λ), we calculated AUC, PPV, and
PCF based on the formulas in previous sections.
2.3.2. Results
The OR parameter estimates for variables in the BCRAT and BCRAT+PD+Weight
models are provided in Table 2.1. Note that the two interaction terms that were
included in the BCRAT were not significant in the BCRAT+PD+Weight model and
therefore excluded. The OR estimates for the two strongest risk predictors, Nbiops
and Numrel, became much smaller in the latter model, which may be due to the
correlation between PD and Nbiops and Numrel as shown in Chapter 3. Our es-
timates were slightly different from those in Chen et al. (2008), because we used
coarser post-stratification strata in the PL method. This is mainly to facilitate the
bootstrapping method for obtaining asymptotic variance estimates of the predictive
accuracy statistics. The coarser strata guaranteed that the same post-stratification
can guarantee a reasonable size of each stratum in each bootstrapping sample. The
bootstrapping standard error was very close to the asymptotic standard error in all
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circumstances.
Table 2.2: Estimates of Predictive Accuracy Statistics for the BCRAT and its Vari-
ants.
Statistics Model Estimates (SD)
PPV (95% risk)
BCRAT 0.008 (0.001)
BCRAT+PD+Weight 0.009 (0.001)
BCRAT+SNP 0.009 (0.001)
BCRAT+PD+Weight +SNP 0.012 (0.002)
AUC
BCRAT 0.607 (0.011)
BCRAT+PD+Weight 0.659 (0.012)
BCRAT+SNP 0.674 (0.009)
BCRAT+PD+Weight +SNP 0.706 (0.007)
PCF (q=0.1)
BCRAT 0.209 (0.018)
BCRAT+PD+Weight 0.258 (0.015)
BCRAT+SNP 0.254 (0.006)
BCRAT+PD+Weight +SNP 0.299 (0.011)
PCF (q=0.2)
BCRAT 0.356 (0.029)
BCRAT+PD+Weight 0.400 (0.018)
BCRAT+SNP 0.413 (0.008)
BCRAT+PD+Weight +SNP 0.466 (0.013)
PCF (q=0.3)
BCRAT 0.460 (0.033)
BCRAT+PD+Weight 0.524 (0.019)
BCRAT+SNP 0.541 (0.009)
BCRAT+PD+Weight +SNP 0.592 (0.012)
PCF (q=0.4)
BCRAT 0.721 (0.067)
BCRAT+PD+Weight 0.630 (0.018)
BCRAT+SNP 0.647 (0.010)
BCRAT+PD+Weight +SNP 0.694 (0.011)
The estimates of predictive accuracy statistics for the four models are provided in
Table 2.2. The standard deviations were obtained by bootstrapping 1000 samples
from the BCDDP. We first generated 1000 samples from the original data by sampling
with replacement from each stratum defined by case-control status and age groups.
With each bootstrapping sample, we estimated (β,θ). Then we applied parametric
bootstrapping to generate 1000 sets of X from the estimated p(X|A) and its variance-
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covariance matrix from NHIS dataset. Finally, we parametrically bootstrapped 1000
sets of βw with the estimated log ORs and variances from literature. We then obtained
1000 sets of estimates (βˆ, θˆ) and pˆ(X|A). The standard errors of each statistic is then
calculated from the 1000 corresponding predictive accuracy statistics. The calculation
of all predictive accuracy statistics was based on the 5-year risk for 35 year old women.
Adding SNPs and PD lead to large improvement in all predictive accuracy statistics,
and SNPs appeared to have a slightly larger incremental value. PPV was 0.54%,
0.71%, 0.70%, and 0.82% under the BCRAT, BCRAT+PD+Weight, BCRAT+SNP,
and BCRAT+PD+Weight+SNP, respectively. The PPV of the BCRAT was 0.0075,
suggesting that 0.75% of the 35 year-old women whose breast cancer absolute risk
was greater than 0.54% (top 5%, high risk) will develop breast cancer by age 40.
The PPV for the other three models were 0.93%, 0.93%, and 1.17%, respectively.
The AUC statistic under the four models were 0.607, 0.659, 0.674, and 0.706. We
computed PCF under different q values. At q = 0.2, the PCF for the four models
were 0.356, 0.400, 0.413, and 0.466, respectively. These results indicated that for the
35 year-old women who will develop breast cancer in the age interval (35, 40), 11%
more will arise among women whose absolute risk exceeds the 80% percentile in the
population as calculated by each model. PCF at the other q values showed similar
results.
2.4. Simulation Study
We then conducted extensive simulation studies to 1) assess the finite sample perfor-
mance of the asymptotic standard error estimates for predictive accuracy statistics,
and 2) assess the performance of normal approximation to the distribution of risk
score U when a large number of predictors with small effects, such as SNPs, are in-
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corporated from external sources. We designed the simulation studies so that the
distribution of risk predictors was similar to that in the BCDDP. Therefore, we ex-
pect that our simulation results will also yield insights on the performance of variant
BCRAT models.
To generate two-phase stratified case-control samples, we first simulate a population
under the true model with all predictors and SNPs as follows. We first generated for
each subject data on age A, five predictors X = (X1, X2, X3, X4, Z), and external
predictors W = (W1,W2, ...,Wl). The age group indicator IA was obtained as IA = 1
for 30 ≤ A < 40, IA = 2 for 40 ≤ A < 50, IA = 3 for 50 ≤ A < 60, IA = 4 for
60 ≤ A < 70, and IA = 5 for A ≥ 70, where A was generated from a uniform distribu-
tion Uniform(30, 80). X1 took values 0, 1, 2 and 3 and X2 values 0, 1 and 2 with the
frequency of each value similar to that of Ageflb and Agemen in the BCDDP, respec-
tively. X3 were generated from Poisson(0.8) and X4 from Poisson(0.2) by assigning
values 0, 1, and 2 to categories 0, 1, and ≥ 2, respectively. We generated the contin-
uous Z measurement from Beta distribution, Beta(κφ, φ − κφ), with logit(κ) = Qγ
and log(φ) = Qω, where Q = (1, X,A), and we used for parameters θ = (γ,ω)
similar values as the corresponding estimates in the BCDDP. Then we categorized
Z to create variable Zc taking values 0, 1, 2 and 3 for Z ∈ (0, 0.25), [0.25, 0.50),
[0.50, 0.75) and [0.75, 1), respectively. We generated l independent SNPs, with the
genotype data for each SNPj generated from a multinomial distribution with values
0, 1 and 2 and corresponding probabilities (1− pj)2, 2pj(1− pj) and p2j , where pj was
the minor allele frequency for the jth SNP and j = 1, 2, ..., l. Finally, we generated
case-control status Y from a Bernoulli distribution with probability
p(Y = 1|X,Z,W ) = eαa+Xβx+Zcβz+Wβw (1 + eαa+Xβx+Zcβz+Wβw)−1 , (2.2)
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We treated all predictors as ordinal in the analyses. We then randomly sampled n/5
cases and n/5 controls from each age stratum using variable probability sampling, so
that each case-control sample included n cases and n controls. To create a two-phase
design sample, we randomly sampled a subset of cases and controls stratifying on A
and then deleted data Zc for the rest of case-control subjects.
The estimation of the predictor distribution p(X,Zc,W |A), as required in the esti-
mation of predictive accuracy statistics, requires estimates of parameters θ in the
distribution pθ(Z
c|X,A), p(X|A), and pj. For each dataset, we estimated θ by fitting
a beta regression model to phase II controls only. Because p(X|A) and pj were gen-
erally estimated from external resources, we keep them fixed in the simulation. To
evaluate the normal approximation to the distribution of risk score Xβx+Z
cβz+Wβw
when the number of SNPs is large, we compared results obtained with normal approx-
imation and those with the exact distribution. For the former, we estimated (βx, βz)
for each simulated dataset by fitting model (2.2) but without W using the PL method,
and estimated βw from an independent case-control sample generated from the same
population as described by model (2.2). For the latter, we jointly estimated (βx, βz)
and βw by fitting model (2.2) using the PL method, and we refer to the corresponding
estimates of predictive accuracy statistics as “gold standard”. We considered 2 SNP
predictors in W to make the computation of the exact distribution feasible in this
comparison. Below, We used “Model-XZ” to refer a the model that only used (X,Z)
as predictors, “Model-XZ-SNP” a model that includes both (X,Z) and W but with
(βX , βz) and βw estimated separately as above, and “Model-XZ-SNPgs” the “gold
standard” model.
As shown in Table 2.3, even if we used intentionally large OR values for the two
SNPs, OR parameter estimates for both (X,Z) and W were close to the true values
28
T
ab
le
2.
3:
O
R
E
st
im
at
es
in
S
im
u
la
ti
on
S
tu
d
ie
s
w
it
h
2
S
N
P
s.
O
R
P
ar
am
et
er
M
o
d
el
-X
Z
-S
N
P
gs
M
o
d
el
-X
Z
,
M
o
d
el
-X
Z
-S
N
P
E
st
im
at
es
*
A
sy
m
p
to
ti
c
C
.I
.
C
ov
er
ag
e
E
st
im
at
es
*
A
sy
m
p
to
ti
c
C
.I
.
C
ov
er
ag
e
β
X
1
=
0.
15
0.
14
5
(0
.0
59
,
0.
06
3)
(0
.0
30
,
0.
26
1)
0.
94
0.
13
9
(0
.0
58
,
0.
05
8)
(0
.0
25
,
0.
25
3)
0.
95
β
X
2
=
0.
1
0.
11
0
(0
.0
74
,
0.
08
2)
(-
0.
03
5,
0.
25
6)
0.
93
0.
10
7
(0
.0
73
,
0.
07
7)
(-
0.
03
4,
0.
25
0)
0.
94
β
X
3
=
0.
2
0.
20
0
(0
.0
70
,
0.
07
5)
(0
.0
62
,
0.
33
8)
0.
93
0.
19
6
(0
.0
68
,
0.
07
0)
(0
.0
63
,
0.
32
9)
0.
94
β
X
4
=
0.
65
0.
64
2
(0
.1
18
,
0.
11
8)
(0
.4
10
,
0.
87
4)
0.
95
0.
62
2
(0
.1
13
,
0.
11
4)
(0
.4
00
,
0.
84
4)
0.
94
β
Z
=
0.
4
0.
41
0
(0
.0
73
,
0.
07
6)
(0
.2
67
,
0.
55
4)
0.
94
0.
40
4
(0
.0
70
,
0.
07
1)
(0
.2
67
,
0.
54
0)
0.
94
β
S
N
P
1
=
0.
5
0.
51
2
(0
.0
91
,
0.
09
6)
(0
.3
33
,
0.
69
1)
0.
94
0.
47
7
(0
.0
71
,
0.
07
0)
(0
.3
38
,
0.
61
5)
0.
95
β
S
N
P
2
=
1
1.
00
7
(0
.1
04
,
0.
10
8)
(0
.8
03
,
1.
21
0)
0.
94
0.
97
2
(0
.0
83
,
0.
08
2)
(0
.8
09
,
1.
13
5)
0.
94
*:
P
ar
am
et
er
es
ti
m
at
es
w
it
h
as
ym
pt
ot
ic
st
an
da
rd
de
vi
at
io
n
s
an
d
em
pi
ri
ca
l
st
an
da
rd
de
vi
at
io
n
s.
29
regardless of whether they were estimated jointly or separately, and the asymptotic
standard error estimates were close to the empirical estimates as well. The 95%
confidence intervals provided good coverages as well. Therefore, the potential bias
resulting from fitting a mis-specified model (“Model-XZ”) due to omission of the
two SNPs is small. This observation is owing to the fact that the outcome Y was
rare and that SNPs and the rest of the predictors were independently distributed in
the population. Because we considered strong SNP effects, this same observation is
expected to be generalizable to when a larger number of SNPs with weaker SNPs are
related, as in the variant BCRAT models.
The estimates of predictive accuracy statistics and their standard errors are presented
in Table 2.4. PPV was computed at the 95% absolute risk quantile cutoff, which, un-
der Model-XZ-SNP, was quite close to that under Model-XZ-SNPgs. PPV estimates
were the largest under Model-XZ-SNPgs as expected, and those under model-XZ-
SNP was similar. The average asymptotic and empirical standard errors were close.
For the two SNPs, except for the OR values in Table 2.3, βw = (0.5, 1), we also
considered weaker effects βw = (0.3,−0.15) and stronger effects βw = (1, 2). The
results were largely the same (data not shown). The AUC statistic under the three
models were 0.679, 0.744, and 0.752, respectively. We calculated PCF at different q
values, 0.1, 0.2, 0.3 and 0.4 . Model-XZ-SNP and Model-XZ-SNPgs always had sim-
ilar PCFs, which were greater than that under Model-XZ. As shown by PPV, AUC,
and PCF statistics, although Model-XZ-SNP is a composite approach to evaluating
the predictive accuracy, it performed similar as the gold standard one. In particu-
lar, Model-XZ-SNP led to a conservative assessment of the added value of Z, and
therefore is an appealing first step to assess a potential risk predictor. The average
asymptotic and empirical standard errors were close for the PCF as well although the
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latter was slightly smaller.
Finally, we performed simulation studies with W including 74 SNPs as in the variant
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BCDDP model (Table 2.5). Due to the large number of SNPs, we adopted normal
approximation to the risk score Xβx + Z
cβz + Wβw when computing predictive
accuracy statistics under both “Model-XZ-SNP” and “Model-XZ-SNPgs”. We used
the exact distribution for Xβx + Z
cβz under “Model-XZ”. As observed for the two-
SNP setting, for all the predictive accuracy statistics, we observed large improvement
of Model-XZ-SNP over Model-XZ, and those under Model-XZ-SNPgs were usually
noticeably larger that those under Model-XZ-SNP. For all statistics, the asymptotic
standard error estimate was usually larger than empirical standard error, although
they were reasonably close for Model-XZ and Model-XZ-SNP. The large discrepancy
under Model-XZ-SNPgs might be due to the large dimension of variance-covariance
matrix for the large number of OR parameters. Statistics under Model-XZ-SNP, most
of the time, had smaller empirical standard errors than those under Model-XZ.This
was because Model-XZ-SNP exploited external information for SNP OR parameters
and minor allele frequencies, which were treated as known. Our results suggested
that normal approximation could lead to reasonable albeit conservative assessment
of model performance.
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Table 2.5: Estimates of Predictive Accuracy Statistics in Simulation Studies with 74
SNPs.
Statistics Model Estimates (Asymptotic S.D., Empirical S.D.)
PPV (95% risk)
Model-XZ 0.010 (0.001, 0.001)
Model-XZ-SNP 0.018 (0.006, 0.001)
Model-XZ-SNPgs 0.022 (0.010, 0.002)
AUC
Model-XZ 0.685 (0.021, 0.020)
Model-XZ-SNP 0.759 (0.035, 0.020)
Model-XZ-SNPgs 0.796 (0.118, 0.040)
PCF (q=0.1)
Model-XZ 0.275 (0.036, 0.026)
Model-XZ-SNP 0.407 (0.029, 0.021)
Model-XZ-SNPgs 0.486 (0.079, 0.031)
PCF (q=0.2)
Model-XZ 0.441 (0.038, 0.032)
Model-XZ-SNP 0.580 (0.034, 0.021)
Model-XZ-SNPgs 0.657 (0.101, 0.034)
PCF (q=0.3)
Model-XZ 0.567 (0.036, 0.032)
Model-XZ-SNP 0.696 (0.036, 0.021)
Model-XZ-SNPgs 0.764 (0.115, 0.039)
PCF (q=0.4)
Model-XZ 0.669 (0.032, 0.030)
Model-XZ-SNP 0.780 (0.037, 0.021)
Model-XZ-SNPgs 0.836 (0.124, 0.045)
2.5. Conclusion
The estimators that we proposed for the adapted statistics were model-based, treat-
ing the absolute risk model as the correct model to relate risk predictors and the
probability of developing breast cancer. But this is rarely true in reality. The same
issue arose for predicting binary and time-to-event outcomes, where nonparametric
estimation methods were proposed that were robust to model mis-specification. How-
ever, in the setting of the widely applied composite approach to the development of
cancer absolute risk prediction models, nonparametric estimation methods are not
feasible without a prospective cohort that provides full information on risk predictors
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and events. Our method allows investigators to have at least an initial look at the
added values of candidate predictors.
The efficiency of estimating the adapted statistics depends on the efficiency of es-
timating the OR association parameters and the distribution of risk predictors. In
our current work, the PL method is not fully efficient for estimating OR association
parameters, and parameters in the conditional distribution of the new predictor was
estimated from phase II controls. It is of great interest to develop more efficient
methods for estimation. In Chapter 3, we propose a semiparametric maximum likeli-
hood approach (MLE) to estimating these two sets of parameters, which is expected
to lead to more efficient estimates of the adapted accuracy statistics. On the other
hand, the PL method is robust to the specification of the distribution of the new
predictor, but the semiparametric MLE can yield biased estimates of OR parameters
if the distribution of the new predictor is mis-specified. This bias and efficiency trade
off needs to be carefully considered for deciding which method to use in data analysis.
Our evaluation of combined values of PD and breast cancer risk SNPs relied on
multiple assumptions in order to utilize data in the literature on SNP minor allele
frequencies and OR parameter estimates. But SNPs may contribute to the variation
in the distribution of non-genetic risk predictors such as PD and family history of
breast cancer, and estimates of the OR parameters in the literature from marginal
analysis are biased for those in the logistic model that includes both genetic and non-
genetic risk predictors. Nevertheless, in the absence of data that provides information
on all predictors, this approach allows initial exploration of the combined values of all
predictors. Our simulation studies indicated that this approach provides reasonable
approximation at least for breast cancer risk prediction in the general female popula-
tion. Equally importantly, our results revealed that the approximation is conservative
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in estimating the added values. Our results showed that incorporating PD and the
74 breast cancer risk SNPs improves the predictive accuracy of the BCRAT in term
of PPV, AUC and PCF, and that PD adds similarly as the breast cancer risk SNPs.
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CHAPTER 3
Semiparametric Maximum Likelihood Estimation with
Two-Phase Stratified Case-Control Sampling
36
3.1. Introduction
Cancer absolute risk is the probability that an individual will develop cancer in a
certain age period without dying from competing causes. Its computation involves
the relative hazard function, the age specific baseline hazard, and age specific com-
peting risk hazard. The relative hazard function can be approximated by the odds
ratio (OR) function of the predictors since cancer outcomes are rare. The baseline
hazard rates can be calculated from composite hazard rates available from population
databases such as the Surveillance, Epidemiology, and End Results (SEER) program
when coupled with the OR function and distribution of risk predictors. The hazard
rates of mortality can be obtained from the National Death Index. This composite
approach to cancer risk projection was first used by Gail et al. (1989) to develop the
breast cancer assessment tool (BCRAT), commonly referred to as the “Gail model”.
The BCRAT is the current National Cancer Institute (NCI) standard for predicting
breast cancer absolute risk. It has been widely used for designing clinical trials and
counseling individual woman. It has recently also been evaluated for its usefulness in
designing model-based breast cancer screening program.
The BCRAT includes four risk predictors, age at menarche (Agemen), age at first
live birth (Ageflb), number of previous breast biopsies (Bbiops), and number of first-
degree relatives (mother/sisters) (Numrel) who had breast cancer. It calibrates well
but only has a modest discriminatory accuracy with the area under the ROC curve
(AUC) ranging from 0.58 to 0.64 (Costantino et al., 1999; Freedman et al., 2005;
Rockhill et al., 2001). Therefore, it has been of great interest to increase the pre-
dictive accuracy of the BCRAT by incorporating emerging risk predictors. Percent
mammographic density (PD), which is a measure of breast density as the percent of
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dense area on the mammogram image, has recently been established to be one of the
strongest risk predictors for breast cancer. Chen et al. (2006) and Chen et al. (2008)
developed an OR function and the corresponding absolute risk prediction model that
included PD as a new predictor, and found that it led to a modest increase in the
AUC statistic. Breast cancer risk associated SNPs, independently or combined with
PD, have recently been extensively evaluated for their added values in improving
breast cancer risk prediction. In Chapter 2, we adapted several statistics for evaluat-
ing the accuracy of models developed with binary or time-to-event outcome data to
accommodate the composite approach to absolute risk prediction, and assessed the
combined value of PD and the 74 breast cancer risk SNPs for improving the accuracy
of the BCRAT.
In Chapter 2, for the BCRAT and its variants, we used data for risk predictors
and PD from the Breast Cancer Detection and Demonstration Project (BCDDP).
BCDDP started from 1973 and was originally designed to assess whether mammo-
graphic screening can reduce morbidity and mortality of breast cancer. It recruited
243,221 white women in 1973 to 1975 and followed up each subject for at least 5
years. An age-stratified case-control study was conducted in 1979, and the BCRAT
risk predictors were available for all 2808 cases and 3119 controls. But only 1217
cases and 1616 controls had PD measurements available. SNP genotype data was
not available from the BCDDP. The challenge of incomplete predictor data as in the
BCDDP in the development of absolute risk prediction models is widespread. For
example, it may require up-to-date high technology to measure emerging risk factors,
which may be too expensive or technically infeasible to use on all subjects. One such
example is estrogen metabolomic measurements. It may also be possible that geno-
type data cannot be make available for all subjects. When standard risk predictors
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are available from a stratified/frequency-matched case-control study but candidate
predictors are only collected on a subset, the data can be viewed as arising from
a two-phase stratified case-control design. In phase I, the case-control status and
standard risk predictors are collected on all cases and controls. In phase II, costly
predictor is measured on a subset selected based on case-control status and phase I
variables. The incomplete data conforms to a missing at random mechanism (Little
and Rubin, 1987) because the missingness occurred by study design. The develop-
ment of statistical methods for analysis has been focused on integrated analysis of
phase I and phase II data to achieve increased precision for estimating OR parameters
that quantify associations between the binary outcome and risk variables (Breslow
and Cain, 1988; Breslow and Chatterjee, 1999; Breslow and Holubkov, 1997; Chen
et al., 2008; Scott and Wild, 1997). In particular, Chen et. al (2006, 2008) carried
out a pseudo-likelihood approach to analyzing the two-phase stratified case-control
data and derive the OR function. This approach was applied to analyze the BCDDP
data in Chapter 2.
We are interested in developing a more efficient approach to estimating cancer ab-
solute risk and predictive accuracy statistics developed in Chapter 2, which requires
efficient estimation of both OR parameters and the joint distribution of standard and
candidate predictors given age. Usually the distribution of standard risk predictors
can be obtained from national population databases, which is preferable to assure the
applicability of the model to the general population. But candidate predictors are
often not included in these databases. Therefore, our goal involves efficient estimation
of the OR parameters and conditional distribution of the candidate predictor given
standard predictors and age. Here, we propose a semiparametric maximum likeli-
hood estimation (MLE) method for jointly estimating parameters in the distribution
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of the candidate predictor and the OR parameters using data from both phase I and
phase II subjects. In addition, Chen et al. (2006) studied large sample approxima-
tion to the distribution of their proposed pseudo-likelihood estimator, but they did
not assess the finite sample performance of their estimator nor the accuracy of the
large sample approximation to the distribution. Through extensive simulation stud-
ies and application to the analysis of the BCDDP data, we fully evaluate the finite
sample performance of our new and the pseudo-likelihood estimators. In particular,
we evaluate the corresponding efficiency gain for estimating OR parameters as well
as statistics for quantifying predictive accuracy when these approaches are used in
the development of the BCRAT that incorporates PD.
3.2. Methods
To simplify the notation, we assume that sampling of cases and controls was stratified
on a single matching variable. Let Y denote the case-control status, X the collection
of standard predictors, Z the new predictor and A the matching variable. We use Ia
to denote the ath matching category. We assume that Z is univariate, which is quite
common in practice. But the proposed methods are general and can accommodate
multivariate Z. Data onX is collected for n1 cases and n0 controls who are matched on
Ia, and Z is collected only for a subset of m1 cases (m1 ≤ n1) and m0 controls (m0 ≤
n0). In addition, auxiliary information for Z, denoted as S, is often conveniently
available for all n1 +n0 subjects. For example, weight is strongly correlated with PD
and thus can be useful as auxiliary information. We quantify the association between
Y and (X,S, Z,A) with a logistic regression model
logitp(Y = 1|X,S, Z,A) = αa + βTxX + βsS + βzZ, (3.1)
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where αa denotes the stratum-specific intercept parameter for A ∈ Ia and the su-
perscript T denotes the vector transpose. Let β = (βx, βs, βz). We are interested
in efficient estimation of β and the distribution p(Z|X,S,A), but not in estimating
the distribution of standard predictors p(X,S|A). Because cancer is fortunately rare,
the probability density function p(Z|X,S,A) for the population can be well approx-
imated by that in the control population, p(Z|X,S,A;Y = 0). We incorporate S in
the conditioning variables because it is predictive of Z. Using a parametric distribu-
tion to model p(Z|X,S,A;Y = 0) with parameter θ, we propose a semiparametric
Maximum Likelihood Estimation (MLE) method that jointly estimates β and θ. The
estimation of predictive accuracy statistics proposed in Chapter 2 requires estimation
of the joint predictor distribution p(X,S, Z|A;Y = 0), which can then be obtained
as pθ(Z|X,S,A;Y = 0)p(X,S|A;Y = 0), where p(X,S|A;Y = 0) is estimated non-
parametrically from external resources.
3.2.1. Estimation of β and θ
We assume that the first m1 cases and first m0 controls have Z measurements. The
logarithm of the likelihood function can be written as
m1+m0∑
i=1
log p(Xi, Si, Zi|Ai, Yi) +
n1+n0∑
i=m1+m0+1
log p(Xi, Si|Ai, Yi).
Let n1a denote the number of cases in the a
th matching category Ia. Recognizing that
p(X,S, Z|A, Y = 1) can be written as (Satten and Carroll, 2000; Satten and Kupper,
1993)
eβ
T
xXi+βsS+βzZp(X,S, Z|A, Y = 0)
{∑
X,S,Z
eβ
T
xX+βsS+βzZp(X,S, Z|A;Y = 0)
}−1
,
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the log likelihood function can be further written as
m1+m0∑
i=1
log
{
eYi(β
T
xXi+βsSi+βzZi)pθ(Zi|Xi, Si, Ai;Yi = 0)
}
+
n1∑
i=m1+1
log
{∑
Z
eβ
T
xXi+βsSi+βzZpθ(Z|Xi, Si, Ai;Y = 0)
}
+
n1+n0∑
i=1
log p(Xi, Si|Ai;Yi = 0)
−
∑
a
n1a log
[∑
X,S,Z
eβzZ+β
T
xX+βsSpθ(Z|X,S,A ∈ Ia;Y = 0)p(X,S|A ∈ Ia;Y = 0)
]
A noteworthy feature of this likelihood is that the matching stratum-specific intercept
parameter αa is not involved, so that it is a function only of (β,θ) and p(X,S|A, Y =
0). Let ψ = (β,θ). We do not model the nuisance function p(X,S|A, Y = 0). Here,
we derive the profile likelihood for parameters ψ, and obtain the MLE estimate ψˆ
by maximizing the profile likelihood. To this end, for the jth unique combined value
of X, xj, and the l
th unique value of S, sl, in the a
th matching stratum, we place a
point mass on p(X,S|A, Y = 0) as δjla, which satisfies
∑
j,l δjla = 1. Let δ denote
the vector of all δjla’s, and let njla denote the total number of cases and controls with
X = xj and S = sl in the a
th matching stratum. Let na =
∑
j,l njla, which is the
total number of cases and controls in the ath matching stratum, and n0a = na − n1a,
which is the number of controls in the ath matching stratum. Let Q = (X,S, Z) and
K = (X,S,A), and write the observed values for Q and K on the ith subject as
Qi = (Xi, Si, Zi) and Ki = (Xi, Si, Ai), respectively. Write pθ(Z|Xi, Si, Ai;Y = 0) as
pθ(Z|Ki) to simplify the notation. Further, let Qjlz = (X = xj, S = sl, Z = z), and
write pθ(Z|X = xj, S = sl, A ∈ Ia;Y = 0) as pθ(Z|Kjla). Note that both Q and K
include variables (X,S). We write βTxXi + βsSi + βzZi as Qiβ. Then the empirical
log likelihood function is obtained by replacing p(X,S|A, Y = 0) by δjla in the above
42
likelihood:
`(ψ, δ) =
m1+m0∑
i=1
log
{
eYiQiβpθ(Zi|Ki)
}
+
n1∑
i=m1+1
log
{∑
Z
eQiβpθ(Z|Ki)
}
+
∑
jla
njla log δjla −
∑
a
n1a log
{∑
j,l,Z
eQjlZβpθ(Z|Kjla)δjla
}
.
If (X,S) only has a small number of unique values, then estimates (ψˆ, δˆ) can be
obtained by applying the standard Expectation-Maximization (EM) algorithm. But
(X,S) may have many values in reality, as X may have many unique values and S can
be continuous. It is well known that the EM algorithm often breaks down when the
data is sparse relative to the number of parameters. We derive the profile likelihood
function for ψ, which involves only the parameters of interest ψ = (β,θ) and a set
of new nuisance parameters µ = {µa} with length equal to the number of matching
strata (see Appendix A.1.1):
`p(ψ,µ) =
m1+m0∑
i=1
log
{
eYiQiβpθ(Zi|Ki)
}
+
n1∑
i=m1+1
log
{∑
Z
eQiβpθ(Z|Ki)
}
+
∑
a
n0a log µa +
∑
jla
njla log njla
−
∑
jla
njla log
{
n0aµa + n1a
∑
Z
eQjlZβpθ(Z|Kjla)
}
.
where µa =
∑
j,l,Z e
QjlZβpθ(Z|Kjla)δjla. In Appendix A.1.2, we showed that µ can
be treated as an independent set of parameters in the profile likelihood function. We
maximize `p(ψ,µ) jointly over ψ and µ, and refer to the resultant maximizer ψˆ as
the semiparametric MLE of ψ. The large sample properties of ψˆ is summarized in
Theorem 3.1 below.
Theorem 3.1. Under suitable regularity conditions, we show that
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√
n
(
ψˆ −ψ
)
D−→ N(0,W ). 
Here W is the large sample limit of − 1
n
∂2`(ψ,µ)
∂ψ2
. Since 0 = ∂`
p(ψˆ,µ)
∂ψ
= ∂`
p(ψ,µ)
∂ψ
+
∂2`p(ψ,µ)
∂ψ2
(
ψˆ −ψ
)
, we obtain that
√
n
(
ψˆ −ψ
)
→
[
− 1
n
∂2`(ψ,µ)
∂ψ2
]−1√
n 1
n
∂`(ψ,µ)
∂ψ
. We
show that − 1
n
∂2`(ψ,µ)
∂ψ2
P−→ W−1 and √n 1
n
∂`(ψ,µ)
∂ψ
D−→ N(0,W−1), which proves Theorem
3.1. More detailed proof is provided in Appendix A.1.3. Thus we show that ψˆ is
consistent, asymptotically normally distributed, and semi-parametric efficient.
We will compare the performance of our semiparametric MLE method with the
pseudo-likelihood (PL) method described in Chapter 2 (Chen et al., 2008). Our
method is likelihood-based and therefore expected to be more efficient than the PL
method. When Z is fully available for all n1 cases and n0 controls, PL estimates
are the same as those from the standard prospective analysis of case-control data
(Prentice and Pyke, 1979), but estimates from our MLE method are expected to be
more efficient due to the modeling of conditional distribution p(Z|X,S,A). Estima-
tion of the absolute risk and corresponding predictive accuracy statistics with the risk
score Qβˆ can then proceed as described in Chapter 2. In particular, the estimates
of both β and θ are involved, and θ needs to be estimated from phase II controls
when using the PL method for estimating β. Estimation of the predictive accuracy
statistics is expected to derive efficiency improvement from the MLE method through
the estimation of both β and θ.
3.3. The analysis of BCDDP data
We apply the proposed method to analyze the BCDDP two-phase age-stratified
case-control data, the details of which were provided in Chapter 2. Let X1, X2,
X3, X4, S, and Z denote the four standard predictors age at menarche (Agemen),
age at first live birth (Ageflb), number of previous breast biopsies (Nbiops), and
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number of first-degree relatives (Numrel), weight, and PD, respectively, and X de-
notes (X1, X2, X3, X4). All 3119 controls and 2808 cases had complete data for
X = (X1, X2, X3, X4), S and A, among whom 1616 and 1217 had data on PD. We
used a zero-inflated Beta regression model for the distribution of Z to accommodate
excess zero values for Z. In BCDDP, around 10% of the subjects had zero values
for PD. Women who had zero values may truly had no dense tissues that could be
captured by the mammogram, or the percentage was too low to be detectable. The
estimates can be biased if some zero values actually mean that Z < Zmin where Zmin is
the minimal value that PD is detectable. In the zero-Inflated Beta regression model,
both the mean and precision parameters of the beta distribution are functions of risk
predictors. Let ρ denote the probability that Z truly takes zero value and 1− ρ the
probability that the Z values follow a beta regression model. The probability density
function for Z can be written as
p(Z|X,S,A;γ,ω, ρ) = p(Z = 0)I(Z=0)p(Z > 0)I(Z>0)
= [ρ+ (1− ρ)Beta(Z < Zmin|K∗;γ,ω)]I(Z=0)
× [(1− ρ)Beta(Z|K∗;γ,ω)]I(Z>0)
where K∗ = (1, K) = (1, X, S,A), Beta(Z|K∗;γ,ω) is written as Beta(Z|κ, φ) =
Γ(φ)
Γ(κφ)Γ(φ−κφ)z
κφ−1(1 − z)φ−κφ−1, and logit(κ) = K∗γ and log(φ) = K∗ω. Slightly
different from what we did in the simulation studies below, in the logistic regression
model for Y , we categorized Z into 5 groups taking values 0, 1, 2, 3 and 4 for
Z = 0 or Z ∈ (0, Zmin), [Zmin, 0.25), [0.25, 0.50), [0.50, 0.75) and [0.75, 1), respectively.
Therefore, estimates of OR parameters using the PL method are not the same as
those in Chen et al. (2008) because here we have an additional “0” category instead
of combining 0 into the [0, 0.25) category as in Chen et al. (2008).
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We first fitted a full model that includes all the variables (Ageflb, Agemen, Nbiops,
Numrel, Weight, PD, Age) in the logistic regression model, and results are presented in
Appendix Table B.8. All predictors in the association model appeared to be significant
with p-values smaller than 0.05. In the Z model, Numrel was not significant in the
mean model, and Ageflb, Agemen, and Numrel were not significant in the variance
model. Therefore, we removed them from these two models in the final analysis. The
zero inflation parameter ρ was estimated to be 0.11 and appeared to highly significant.
The estimates of the OR parameters in the final model are presented in Table 3.1.
OR estimates from the two methods appeared to be close. The averaged asymptotic
variance estimates of the MLE method were close to the empirical variances (data
not shown). The coverage of the 95% confidence intervals was close to the nominal
value 95%. The MLE estimates had smaller variance and shorter 95% confidence
intervals than the PL method, suggesting higher efficiency. In the variance model for
Z, the parameter for Nbiops appeared not significant by the PL method but highly
significant by the MLE method. Interestingly, both weight and PD were positively
associated with the risk of breast cancer, but weight itself was negatively associated
with the distribution of PD.
We then compared the efficiency of estimating the AUC statistic corresponding to
the MLE and PL methods. Cases and controls were matched on the baseline age
(A) within 5-year intervals. Then A agrees with t0 in the estimation of the ab-
solute risk. Therefore t0 in the absolute risk and TPR/FPR formulas can be re-
placed by A. Then p(Z|X,S, t0) in absolute risk estimation is directly written as
pθ(Z|K) = pθ(Z|X,S,A, Y = 0) as in the restrospective MLE method (see the profile
likelihood `p in section 5.2.1). In the calculation of the attributable risk AR(t) = 1−
1/
∑
Q p(Q|t)r(Q;β) and the distribution of U , Fˆ (U ; βˆ) =
∑
Q I
[
Qˆβ ≤ U
]
pˆ(Q|t0),
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where notations are the same as those in Chapter 2, both t and t0 are age A. Then
p(Q|t0) is obtained by pθ(Z|X,S,A, Y = 0)p(X,S|A), where θ is estimated from the
profile likelihood in section 5.2.1, and p(X,S|A) from population databases.The AUC
statistic based on the lifelong absolute risk estimates (from age 30 to 80) was around
0.67 by both methods. The MLE method has narrower confidence interval ([0.644,
0.688]) than PL method ([0.647, 0.697]) and therefore produced more accurate statis-
tic for predictive accuracy evaluation (see Appendix Table B.9).
We also performed the Pearson’s Chi-squared Test to check the goodness-of-fit of the
zero-inflated Beta regression model (Appendix Table B.11). There appeared to be no
significant discrepancy between the estimated and observed PD values (p-value= 0.4)
when model parameters were estimated from the MLE. But the p-value based on
parameters estimates using phase II controls only was 0.03. We plotted a histogram
of the observed and estimated PD values in controls only (see Appendix Figure B.1).
3.4. Simulation Study
We conducted extensive simulation studies to assess the finite sample performance
of the proposed estimators and the associated statistics for quantifying predictive
accuracy. We also compared the statistical efficiency of our new MLE and the PL
method.
We first generated a population as follows. We generated data on matching vari-
able A from the uniform distribution Uniform(30, 80), standard predictors X =
(X1, X2, X3, X4), S, and predictor Z. The age group indicator IA was created as
IA = 1 for 30 ≤ A < 40, IA = 2 for 40 ≤ A < 50, IA = 3 for 50 ≤ A < 60,
IA = 4 for 60 ≤ A < 70, and IA = 5 for A ≥ 70. X1 and X2 took values 0, 1,
2 and 3 where the frequency of each value mimicked that of Agemen and Ageflb
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observed in the BCDDP. X3 and X4 were created from Poisson random variables
Poisson(0.5) and Poisson(1) by assigning values values 0, 1, or 2 to 0, 1, ≥ 2. Fur-
ther, we generated S from N(170, 202) (S ∈ [80, 300]) and was categorized in to 6
groups taking values 0 for S ≤ 100, 1 for S ∈ (100, 125], 2 for S ∈ (125, 150], 3
for S ∈ (150, 175], 4 for S ∈ (175, 200] and 5 for S > 200. We generated contin-
uous Z measurements from a Beta distribution Beta(κφ, φ − κφ), Z ∈ (0, 1), with
logit(κ) = K∗γ and log(φ) = K∗ω, where K∗ = (1, X, S,A). Note that the Z val-
ues generated by Beta distribution will be between 0 and 1 thus have no 0 values.
We chose values for parameters θ = (γ,ω) in the Beta distribution. We consid-
ered both continuous and categorized Z, where the categorized Z was denoted as Zc
taking values 0, 1, 2 and 3 for Z ∈ (0, 0.25), [0.25, 0.50), [0.50, 0.75), and [0.75, 1),
respectively. All variables, X1, X2, X3, X4, S, and Z
c, were treated as ordinal.
Case-control status Y was generated from a Bernoulli distribution with probability
p(Y = 1) = eαa+β
T
xX+βsS+βzZ
c
(
1 + eαa+β
T
xX+βsS+βzZ
c
)−1
with chosen values of αa for
age group a, βTx = (βx1 , βx2 , βx3 , βx4), βs and βz.
We then selected N cases and N controls stratified on IA using variable probability
sampling. We obtained N/5 cases and controls from each age group, resulting in a
case-control sample with sample size 2N . N took values 500, 1000 or 2000. To create
a two-phase stratified case-control sample, we deleted data Z and Zc from a subset
of cases and controls while retaining data on (Y,X, S,A) for all cases and controls by
selecting an equal number of cases and controls within each age stratum. We repeated
this process 1000 times and obtained 1000 such case-control samples.
We evaluate the following aspects of our methods in the simulation study: (1) The
consistency of our MLE methods for estimating (β,θ); (2) Coverage for testing (β,θ);
(3) The efficiency for estimation of our MLE method and PL method.
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Figure 3.2: Area under the ROC Curve in Simulation Studies.
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Figure 3.1 shows all the parameter estimates with their confidence intervals. Each
small plot is for each parameter. Taking the parameter for S in the mean model for
Z as an example, all estimates appeared to be very close to their corresponding true
values. The MLE method yielded more efficient estimates that have narrower confi-
dence interval than PL method. Surprisingly, for this parameter, the MLE estimates
with a sample size 100 were more efficient than the PL estimates with doubled sam-
ple size. The same thing happens when we have sample size 2000, while PL method
has sample size 4000. For all the other parameters in this plot, we always see that
the MLE method is more efficient than PL method. The predictive accuracy statistic
AUC, where the absolute risk was for 10 year age interval from 30 to 40 or the lifelong
age interval from 30 to 80 (Figure 3.2) had noticeable variances when the MLE was
adopted.
3.5. Conclusion
Our proposed method was more efficient than the existing method in terms of OR
estimates and statistics for predictive accuracy. Besides AUC, estimation of the other
statistics presented in Chapter 2 was more efficient as well with the MLE method.
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Taking PPV as example, when the subjects with top 50% absolute risk are categorized
as high risk, PPV is around 0.23 using both MLE and PL method, while the standard
deviation is 0.005 for the MLE method and 0.006 for the PL method (see Appendix
Table B.10).
Our method can easily be extended to risk prediction for other diseases, which may
have emerging new predictors that are either missing at random or too expensive
to be obtained. Then one can try to obtain the predictor in a subset of subjects.
Even if the new predictor has no missing values, we still gain efficiency with our
method. Other covariates not in the association model can also be included into the
conditional distribution for Z in addition to the standard predictors. Our method
requires correct specification of the conditional distribution for Z. One can always
check whether a distribution works well and whether you have correctly specified the
distribution for the new predictor.
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CHAPTER 4
Evaluation of the Added Value of Percent
Mammongraphic Density and SNPs in Breast Cancer
Absolute Risk Projection
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4.1. Introduction
As new strategies for early detection and prevention of breast cancer become avail-
able, including MRI screening (Saslow et al., 2007) and chemoprevention (Thomsen
and Kolesar, 2008), it is essential to provide accurate risk assessment tools for iden-
tifying women at high risk of breast cancer. The accuracy of risk stratification can
be improved through incorporation of emerging risk predictors. Breast density, as a
widely recognized independent risk predictor, and breast cancer risk associated SNPs,
have recently been extensively evaluated for their added values in improving risk pre-
diction models. A Swedish study showed that adding percent mammographic density
(PD), body mass index, and 18 breast cancer risk SNPs can improve the AUC of a
Swedish risk prediction model from 0.55 to 0.62. A theoretical study conducted in the
United Kingdom population showed that a 76-locus polygenetic risk score can lead
to improved risk stratification and added more than the BI-RADS breast density. In
the Breast Cancer Surveillance Consortium (BCSC) risk prediction model, the 80-
locus polygenetic risk score was shown to predict independently of BI-RADS breast
density. It improved the BCSC model that also includes BI-RADS breast density as
a predictor, increasing AUC from 0.66 to 0.69 and more accurate classification of the
high-risk women.
We assess the incremental values of PD and breast cancer risk associated SNPs dis-
covered to date for improving the breast cancer risk assessment tool (BCRAT) (Gail
et al., 1989) for risk stratification, and thereby assess their potential in improving
model-based breast cancer screening in the United States female population. BCRAT
is one of the most widely used risk prediction model for identifying high risk women,
but it has only modest discriminatory accuracy with an area under the ROC curve
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(AUC) in the range of 0.58∼0.67 across studies (Costantino et al., 1999; Freedman
et al., 2005; Rockhill et al., 2001). PD, the percent dense area on the mammographic
image, is a two-dimensional objective measure of breast density that is now auto-
matically provided by most breast image processing software. It has been validated
to be a reliable risk predictor that has high attributable risk. Incorporation of PD
into the BCRAT was found to lead to a modest increase in AUC (Chen et al., 2008).
In addition, a small number of genetic susceptible variants for breast cancer (Gail,
2008; Wacholder et al., 2010) were found to lead to a much smaller increase in AUC
than the PD. To our best knowledge, no data is available yet for quantifying the
values of PD and breast cancer risk SNPs together in improving risk stratification in
the U.S. female population. Currently, the U.S. Preventive Task Force recommended
not to routinely screen women aged 40-49 years, which has been heavily debated by
the radiology society. We therefore calculate the percentage of women in the United
States aged 40-49 years whose breast cancer risk is higher than the risk threshold for
chemoprevention.
4.2. Methods
We calculate the proportion of to-be-developed breast cancer cases in the U.S. female
population whose absolute risk is in the upper qth quantile of the population, and
the upper risk quantile of the population that needs to be followed so that a pro-
portion p of women who will develop breast cancer will be captured. Here q and p
are pre-specified numbers. These two measures, termed proportion of cases followed
(PCF) and proportion of subjects needed to follow (PNF), were proposed for evaluat-
ing model accuracy for predicting binary outcomes. We adapted them for evaluating
cancer absolute risk models in the presence of incomplete predictors as follows. Let
the absolute risk in the age interval (A,A+τ) as ΨA,τ (U), where U is the risk score ex-
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pressed as logarithm of the relative risk function and ΨA,τ (U) is an increasing function
of U . Let ψ denote a pre-specified risk threshold, and T denote age at cancer diagnosis.
We defined the true positive rate as TPRψ(A, τ) = p {ΨA,τ (U) ≥ ψ|A < T ≤ A+ τ},
one minus the cumulative distribution of projected absolute risk in age interval
(A,A + τ) among individuals who develop cancer in (A,A + τ). We similarly de-
fined FPRψ(A, τ), and calculated AUC accordingly. Let F denote the cumulative
distribution function of U and F = 1 − F Then PCF(A,A+τ)(q) = TPRF−1(q)(A, τ),
and its inverse function PNF(A,A+τ)(p) = PCF
−1
(A,A+τ)(p).
The estimation of these measures for models with and without including PD and
breast cancer risk associated SNPs using BCDDP data and SNP odds ratio parame-
ters and minor allele frequencies in the literature were presented in Chapter 2. These
methods accommodated the multi-step approach for model development and incom-
pleteness of the risk predictor data. The standard risk predictors X in the BCRAT
included six terms, age at menarche (AGEMEN), age at first live birth (AGEFLB),
number of first degree relatives (NUMREL; mother, sister, and daughter) who had
breast cancer, number of breast biopsies (NBIOPS), an interaction term between
age and NUMREL, and an interaction term between AGEFLB and NBIOPS. In the
model that incorporated PD, a different set of variables (X,Z) were included, AGE-
MEN, AGEFLB, NUMREL, NBIOPS, PD, and WEIGHT. We did not have data on
body mass index from the BCDDP.
The estimation of F (U) involves estimation of the distribution for standard BCRAT
predictors and weight, and that of percent PD conditional on these predictors. We
estimated the former using data from the NHAES III data suing a standard weighted
approach for analyzing survey data. We estimated the latter by fitting a zero-inflated
beta-regression model to phase II controls from the BCDDP data as described in
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Chapter 2. We obtained the minor allele frequencies and odds ratio parameter esti-
mates from the literature for the 76 breast cancer risk SNPs identified to date. We
assumed that the risk SNPs are independently distributed and independent of all
other non-genetic risk predictors, and that the effect of risk SNPs is additive to those
of non-genetic predictors on the logistic scale. The details were provided in Chapter
2.
4.3. Results
Among the U.S. women who are between 40 to 49 years old in the U.S., 20.7%,
25.2%, 24.2%, and 29.4% of future breast cancer cases will arise among women whose
predicted 5-year risk is above the 90% quantile by each of the four models, BCRAT,
BCRAT plus SNPs, BCRAT plus PD and WEIGHT, and BCRAT plus SNPs, PD and
WEIGHT. The corresponding AUCs were 0.616, 0.674, 0.658, and 0.702, respectively,
and the positive predictive values were 3.6%, 3.8%, 3.8%, and 4.1% if using 3.0% as
the risk cutoff. The results were similar if the calculation was based on the 10-year
or 5-year risk for women who are 40 years old or 5-year risk for women who are 45
years old (Table 4.3).
Incorporation of PD and breast cancer risk SNPs leads to identification of a higher
proportion of high risk women (Table 4.2). Among the 40 year olds, 1.4%, 2.6%, 2.4%,
4.5% had 5-year absolute risk above 1.67%, the high risk threshold for inclusion of
women in clinical trials. These proportions rose to 7.1%, 12.7%, 12.5%, and 14.9%,
respectively, for the 45 year olds. Notably, 0.7%, 1.8%, 1.7%, and 3.2% of U.S. 45-
year-old U.S. women by the four models have predicted risk above 3.0%, the high risk
threshold for using chemoprevention.
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Table 4.2: Proportion of Women with Absolute Risk Greater than Certain Risk Cutoff
in Each Age Intervals by Model.
Risk Threshold Model
Age Interval
[40, 45] [45, 50] [50, 55] [55, 60]
> 0.0167a
BCRAT 0.014 0.071 0.187 0.339
BCRAT+SNPs 0.026 0.127 0.256 0.390
BCRAT+PD+WEIGHT 0.024 0.125 0.239 0.386
BCRAT+PD+WEIGHT+SNPs 0.045 0.149 0.263 0.376
> 0.03a
BCRAT 0.000 0.007 0.024 0.051
BCRAT+SNPs 0.002 0.018 0.053 0.108
BCRAT+PD+WEIGHT 0.002 0.017 0.056 0.101
BCRAT+PD+WEIGHT+SNPs 0.006 0.032 0.075 0.129
Quantile of the
Mean BCRAT
Riskb
BCRAT 0.710 0.710 0.661 0.661
BCRAT+SNPs 0.628 0.628 0.629 0.629
BCRAT+PD+WEIGHT 0.616 0.613 0.642 0.639
BCRAT+PD+WEIGHT+SNPs 0.637 0.636 0.642 0.641
Quantile of the
Median BCRAT
Riskc
BCRAT 0.407 0.407 0.475 0.475
BCRAT+SNPs 0.521 0.521 0.516 0.516
BCRAT+PD+WEIGHT 0.504 0.486 0.512 0.510
BCRAT+PD+WEIGHT+SNPs 0.549 0.546 0.547 0.545
a: Proportion of women with estimated absolute risk above 0.0167 or 0.03.
b: Quantile of the estimated risk corresponding to the mean BCRAT risk
by each model.
c: Quantile of the estimated risk corresponding to the median BCRAT risk
by each model.
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Table 4.3: Estimates of Predictive Accuracy Statistic by Age Interval, Cutoff and
Model.
Statistics Age Interval Threshold BCRAT BCRATaS BCRAT
a
PD BCRAT
a
PD,S
AUC
[40, 50] - 0.637 0.675 0.665 0.705
[45, 50] - 0.610 0.674 0.659 0.704
[40, 50] - 0.615 0.674 0.657 0.702
[40, 49]
b
- 0.616 0.674 0.658 0.702
PPV
[40, 50]
0.0167 0.025 0.027 0.027 0.030
0.03 0.043 0.041 0.041 0.045
10%c 0.016 0.019 0.019 0.021
[40, 45]
0.0167 0.020 0.022 0.022 0.023
0.03 0.031 0.037 0.037 0.039
10%c 0.011 0.012 0.012 0.013
[45, 50]
0.0167 0.023 0.023 0.023 0.026
0.03 0.037 0.038 0.039 0.041
10%c 0.012 0.014 0.014 0.016
[40, 49]
b
0.0167 0.022 0.023 0.023 0.025
0.03 0.036 0.038 0.038 0.041
10%c 0.012 0.014 0.014 0.015
PCF
[40, 50]
q=0.1 0.207 0.252 0.242 0.292
q=0.2 0.355 0.411 0.396 0.458
q=0.3 0.458 0.539 0.517 0.586
[40, 45]
q=0.1 0.208 0.253 0.244 0.294
q=0.2 0.356 0.413 0.398 0.461
q=0.3 0.459 0.540 0.519 0.588
[45, 50]
q=0.1 0.208 0.253 0.242 0.289
q=0.2 0.355 0.412 0.392 0.456
q=0.3 0.459 0.539 0.520 0.583
[40, 49]
b
q=0.1 0.208 0.253 0.242 0.290
q=0.2 0.355 0.412 0.395 0.456
q=0.3 0.459 0.540 0.516 0.584
a: BCRATS: BCRAT+SNPs; BCRATPD: BCRAT+PD+WEIGHT; BCRATPD,S:
BCRAT+PD+WEIGHT+SNPs.
b: The average statistic based on 5-year risk with starting age ranging in 40∼49.
c: The 10th percentile of the absolute risk calculated in age interval [50, 55].
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Table 4.4: Mean Absolute Risk in Every Quintile by Model.
Risk Quantile Model
Age Interval
[40, 45] [45, 50] [50, 55] [55, 60]
[0%, 20%]
BCRAT 0.004 0.006 0.008 0.011
BCRAT+SNPs 0.003 0.005 0.006 0.008
BCRAT+PD+WEIGHT 0.003 0.005 0.007 0.009
BCRAT+PD+WEIGHT+SNPs 0.003 0.004 0.006 0.007
BCRAT 20% Risk Threshold 0.004 0.007 0.009 0.012
[20%, 40%]
BCRAT 0.005 0.008 0.010 0.013
BCRAT+SNPs 0.005 0.007 0.010 0.013
BCRAT+PD+WEIGHT 0.004 0.007 0.010 0.013
BCRAT+PD+WEIGHT+SNPs 0.005 0.007 0.010 0.013
BCRAT 40% Risk Threshold 0.005 0.008 0.011 0.013
[40%, 60%]
BCRAT 0.005 0.008 0.011 0.014
BCRAT+SNPs 0.005 0.009 0.011 0.014
BCRAT+PD+WEIGHT 0.005 0.009 0.011 0.014
BCRAT+PD+WEIGHT+SNPs 0.005 0.009 0.011 0.014
BCRAT 60% Risk Cutoff 0.005 0.009 0.012 0.016
[60%, 80%]
BCRAT 0.006 0.010 0.013 0.017
BCRAT+SNPs 0.006 0.010 0.014 0.018
BCRAT+PD+WEIGHT 0.006 0.010 0.014 0.018
BCRAT+PD+WEIGHT+SNPs 0.006 0.010 0.014 0.018
BCRAT 80% Risk Threshold 0.007 0.012 0.016 0.020
[80%, 100%]
BCRAT 0.010 0.017 0.023 0.029
BCRAT+SNPs 0.011 0.018 0.024 0.031
BCRAT+PD+WEIGHT 0.011 0.018 0.025 0.032
BCRAT+PD+WEIGHT+SNPs 0.012 0.020 0.027 0.034
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4.4. Discussion
The Swedish study that evaluated the value of PD and SNPs for predicting the risk
of breast cancer reported a similar increase of the AUC from 0.55 to 0.62, although
both values were lower than ours, 0.62 and 0.70. But the Swedish study reported a
much lower added value for PD, which together with BMI increased AUC by 0.019
but the 18 SNPs by 0.067. Our results showed a largely comparable values for PD
(together with WEIGHT) and 76 SNPs with the latter slightly more predictive. Our
results showed that utilization of PD and 76 SNPs in breast cancer screening among
the 40 to 49 year olds can lead to capture of 8.7% more future cases compared to that
using BCRAT, which was higher than the 5.0% reported in the Swedish study (from
35.1% to 40.1%). A smaller incremental value was reported for BI-RAD densities
(Vachon et al. 2014, Garcia-Closas et al. 2014), which might be due to the lower
intra-observer variability of BI-RADS readings (Darabi et al., 2012b).
We focused on the 40 to 49 year old U.S. women for evaluating the efficiency of
an ideal breast cancer risk screening program where each woman is under constant
surveillance to ensure immediate and accurate case identification. We found that the
model with both PD and risk SNPs identify a higher proportion of high risk women
that was above high risk thresholds. Coupled with higher PCF values and with equal
allocation of resources, the models with PD and risk SNPs thus can. Our results
showed that 3.2% of U.S 45-year old women has risk that is above 3.0%. Therefore,
our results suggest that the currently recommendation of not screening women under
50 year olds may be fined using a model-based approach.
Appropriate interpretation of statistical indices requires that the absolute risk model
be well calibrated, which ideally should be assessed in a prospective cohort with
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predictor distribution reflecting that for the targeted population. Without access
to such an ideal cohort, we calibrated models that incorporated PD and/or breast
cancer risk SNPs against the BCRAT which is known to be well calibrated, an indirect
approach used in our previous work (Freedman et al., 2005). The averaged absolute
risk estimates by all models were close in all age intervals and in subgroups defined
by the BCRAT risks (Tables 4.1, 4.4). Therefore, all models considered appeared to
be well calibrated.
Lastly, because the BCRAT is one of the most widely applied cancer risk prediction
models, and because PD is one of the strongest risk predictors owing to its large
attributable risk, our results can provide guidance to breast cancer researchers on
using state-of-the-art statistical methods to evaluate new candidate risk prediction
models.
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CHAPTER 5
Using Family Members to Augment Genetic Case-Control
Studies of a Life Threatening Disease
64
5.1. Introduction
In genetic association studies based on case-control data, many cases may not be
available for genotyping only because they did not survive or they are too sick to
participate. Such losses impose an ongoing challenge for research involving important
debilitating or life-threatening conditions, because bias in inference, known as survival
bias or healthy participant bias, will result if those losses are genetically informative.
Survival bias, as one type of selection bias (Rothman, Greenland, and Lash, 2008),
has been recognized as a source of potential bias in many published genetic association
studies (e.g., Chiu et al., 2011; Lacour et al., 2011; Lazarevic et al., 2008; Williams,
Pendyala, and Superko, 2011). It can also be a source of between-study heterogeneity
in meta-analyses of genome-wide association studies (Go¨gele et al., 2012), and may be
responsible for failure to replicate some genetic association signals (Anderson et al.,
2011).
As an example, in a study of young-onset breast cancer we were able to recruit and
genotype slightly over half of the case women who should have been eligible, based on
our eligibility criteria: being diagnosed under age 50 and having a sister participating
in the Sister Study cohort (http://sisterstudy.niehs.nih.gov/English/2sis.htm). The
Sister Study is a cohort made up of more than 50,000 women who had never had
breast cancer themselves at entry, but had a sister who had been diagnosed with
breast cancer. We identified sisters where the proband who had not been directly
studied had her diagnosis under age 50, and we tried to recruit those young-onset
case sisters. A generic population-based genetic control group, as available through
NCI, could be used for case-control analyses but participation was demanding and the
recruitment rate was modest; comparison with population controls could consequently
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be subject to bias.
Current literature is sparse on study designs and statistical methods for addressing
survival bias. Using simulation studies, Anderson et al., 2011 evaluated the extent of
bias by jointly modeling survival and association. The prospective study design was
suggested as an unbiased alternative (e.g., Heikkila¨, Ebrahim, and Lawlor, 2007), but
cohort studies are often infeasible. Alternatively, more stringent eligibility criteria
can be applied to exclude some cases, e.g., based on recent diagnosis, (e.g., Meschia
et al., 2003; Pijpe et al., 2012). But such constraints can lead to substantially reduced
sample size and impose other kinds of selection that limit the generalizability of the
study findings. Here, we develop a family-supplemented design (FSD) that permits
correction or sensitivity analysis of survival bias by genotyping family members. The
central idea is that genotypes of family members of a deceased case can help pro-
vide information on the genotype of the deceased case, and the type of information
depends on which family members are included. With our proposed strategy of geno-
typing cases and controls who are alive and also family members of representative
deceased cases, we describe valid and efficient statistical methods for quantifying ge-
netic associations both with disease and with survival given disease. Our method
could, for example, be applied to the Two Sister Study by genotyping the available
unaffected sister as a proxy for each unavailable case. We show that it can greatly
improve statistical power while simultaneously controlling healthy participant bias.
5.2. Methods
We begin by considering only genetic effects. Let Y (coded as 1 or 0) denote case-
control status. Suppose that among N1 cases, n1 have survived and provided genetic
data. For simplicity of exposition, we assume that genetic data are available for one
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child, possibly together with that for the spouse (the other parent of that child), for
eachof the m = N1−n1 deceased cases, or for a random subset of them. The method
we describe below can be readily extended to incorporate data from multiple offspring
or a mix of available family structures that could include a variety of genetically
informative first-degree relatives, e.g. some siblings or parents of deceased cases, in
lieu of offspring.
Assume that we have genetic data for N0 controls, who are representative of the
control population (i.e., those not studied are missing at random, and if stratified
sampling was used the analysis will also be stratified). We wish to study the asso-
ciation between Y and a di-allelic autosomal single nucleotide polymorphism (SNP),
with major/minor alleles A/a. Let Gi denote the SNP genotype data for subject i,
and let Gfi denote the genotype data of family members for the ith deceased case.
We initially focus on a child/spouse approach and generalize to other family mem-
bers later. When one child of the deceased case and their spouse are accessible,
Gfi = (G
c
i , G
p
i ), where G
c
i and G
p
i denote their respective genotype data. When only
one child or the spouse is accessible, Gfi = G
c
i or G
f
i = G
p
i . G
f
i is coded as missing
when no family member has been genotyped. We assume that a logistic regression
model describes the association between Y and G:
p(Y = 1|G) = e
β0+βf(G)
1 + eβ0+βf(G)
, (5.1)
where f(G) is a function of G that captures the penetrance model of interest, and β
can be a vector. For example, for a co-dominant genetic model, f(G) is a vector with
two indicator functions I(G=1) and I(G=2), and β = (β1, β2). For a log-additive model,
f(G) would be the number of copies 0, 1, or 2 of the minor allele a. Let S coded
as 1/0 indicate the survival of a case (where S = 1 if survived). We assume that
67
cases with genotype g have survival probability qg = p(S = 1|G = g, Y = 1). With
a co-dominant model for survival, different probabilities, q0, q1 and q2 are allowed,
while q1 and q2 are equal when a dominant model is used.
When the genotype G is predictive of both risk of disease and survival given disease,
one cannot assume that fitting model (1) with data from n1 < N1 cases and N0
controls will yield unbiased estimates of the association parameter β. Under FSD, we
consider that genotype data for one child, or the spouse (the child’s biological parent),
or both can be made available for all of the m deceased cases. We develop a maximum
likelihood estimation (MLE) method for estimating the log odds ratio parameter β
with genotype data for the N0 controls and n1 cases and genotype data for the family
member(s) of the m deceased cases. We shall assume Mendelian inheritance and
that the influence of the spouse genotype on risk is only through the implicit genetic
information that the spouse and child genotypes provide about the missing genotype
of the case and not through any mechanism related to genetic population structure,
or effects of the variant on fertility or assortative mating. The likelihood for the
observed data can be written as:
N1∏
i=1
{
[p(Si = 1, Gi|Yi = 1)]Si
[
p(Si = 0, G
f
i |Yi = 1)
]1−Si} N1+N0∏
i=N1+1
p(Gi|Yi = 0). (5.2)
Note that for now we are assuming for simplicity that only survival of cases and
not that of controls is related to the genotype at the studied locus. However, this
likelihood (the right-hand product factor) could easily be expanded to include an
effect of the variant genotype on survival in those without the disease.
We further assume that child’s and spouse’s genotypes are not related to survival,
conditional on the genotype of the case, i.e., p(Si = 0|Gi, Gfi , Yi = 1) = p(Si =
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0|Gi, Yi = 1), and that the family members of cases whose genetic data are available
are representative of case family members in the source population conditional on the
phenotype. Using a result from Satten and Kupper, 1993 to relate p(G|Y = 1) to
p(G|Y = 0),
p(G|Y = 1) = eβf(G)p(G|Y = 0)
/∑
G
eβf(G)p(G|Y = 0),
and by partitioning according to the composite events and applying the assumed
models, the log of the observed-data likelihood function (2) for a rare pheynotype
can be rewritten as:
`(β,p, pa) =
N1∑
i=1
[
Si log
{
p(Si = 1|Gi, Y = 1)eβf(G)p(Gi|Y = 0)
}]
+
N1∑
i=1
[
(1− Si) log
{∑
G
p(Si = 0|G, Y = 1)eβf(G)p(G,G
f
i |Y=0)
}]
−N1 log
{∑
G
eβf(G)p(G|Y = 0)
}
+
N1+N0∑
i=N1+1
log {p(Gi|Y = 0)} .
Under Hardy-Weinberg equilibrium (HWE), random mating, and Mendelian inher-
itance at the test locus in the population from which cases and controls arise, and
assuming a rare phenotype, the probabilities p(G,Gf |Y = 0) and p(G|Gf , Y = 0) are
functions of the MAF, pa (Appendix Table B.12). Let n10, n11, n12 denote the respec-
tive numbers of living cases (the second index) with genotypes AA, Aa, and aa. Let
mjk denote the number of deceased cases whose child’s and spouse’s genotype data,
Gc = j and Gp = k, is available, where j and k take values 0, 1, or 2 corresponding to
genotypes AA, Aa, and aa, respectively. Note that not all combinations are possible;
for example m02 and m20 cannot occur. Let mjc denote the number of deceased cases
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whose child’s genotype Gc = j is available, while the spouse’s genotype data is not.
Define inverse probability-weighted cell counts Nˆ10 = n10/qˆ0, Nˆ11 = n11/qˆ1, and
Nˆ12 = n12/qˆ2, which can be seen as the predicted number of subjects with genotypes
AA, Aa, and aa among the original total of N1 case subjects. Note that, as one
might hope, Nˆ10 + Nˆ
11 + Nˆ12 = N1 (see Appendix). Under co-dominant coding for
both association, f(G), and survival (to study) conditional on disease, we obtain the
maximum likelihood estimated odds ratio (OR) association parameters as
βˆ1 = log
Nˆ11Nˆ00
Nˆ10Nˆ01
and βˆ2 =
Nˆ12Nˆ00
Nˆ10Nˆ02
,
where Nˆ00 = N0 (1− pˆa)2, Nˆ01 = 2N0pˆa (1− pˆa), and Nˆ02 = N0pˆ2a are the expected
numbers of controls with genotypes AA, Aa and aa, respectively, under the rare dis-
ease approximation and HWE. These estimates are of the same form as those obtained
from the two-by-three contingency table that cross-classifies the genotype and case-
control status should the genotype be available for deceased cases, except that the
observed counts are replaced by the estimated (for cases) or expected (for controls)
counts. These estimators are also very similar to those obtained by Chatterjeeb, 2007
for estimating OR association parameters with case-control data under the constraint
of HWE in the control population, where they reported improved statistical efficiency
when the observed numbers of controls were replaced by the predicted under HWE.
The expressions of βˆ1 and βˆ2 involve the estimated survival probabilities qˆ0, qˆ1 and qˆ2.
But it turns out that two of the score functions for the three survival probabilities are
equivalent, resulting in only two independent score equations. One cannot uniquely
solve for three independent parameters from only two equations without additional
constraints. Therefore, these three parameters as well as the two association param-
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eters are not identifiable when a co-dominant model is adopted for both association
and survival. Intuitively, this is because the genotype information of children and/or
spouse is not fully informative in predicting cases genotype. For example, when par-
ents have genotype Aa and aa, one will expect that their childs genotype is Aa with
probability 0.5 and aa with probability 0.5. However, when one child has genotype
aa and the spouse has genotype Aa, one will only know that the case parent has
genotype Aa or aa but cannot estimate the probabilities without taking advantage of
the risk parameters for disease or survival.
When either the association model (1) or the survival model adopts an additional
constraint, the parameters become identifiable. We note that children and spouses’
genotype data are involved in formulas both for β and (q0, q1, q2). Consequently, with
genotype data from children and spouses, it is feasible to obtain maximum likelihood
estimates that are consistent and at the same time assess the magnitude of survival
bias. Below we provide estimates of OR parameters for association and survival
probabilities under two commonly considered models. For each model, we consider
three different scenarios of how family members of deceased cases are available: the
general mixed scenario where genotype data for one child and spouse, or only for one
child, or only for spouse is available for all or for a subset of deceased cases; one child
and spouse scenario where genotype data for one child and spouse is available for some
or all deceased cases; and one child only scenario where genotype data for only one
child is available for all or some of the deceased cases. We also describe an extension
of these results for studying gene-environment interactions. Here the estimates of
log OR for association also resemble those if genotype data were available for cases,
except that the genotype counts for cases and controls are replaced by the estimated
(for cases) and the expected (for controls), respectively.
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5.2.1. Modeling Association as Log-additive and Survival as Co-dominant
Under a log-additive coding for association and co-dominant coding for survival, we
obtained closed-form MLEs that incorporate family genotype data. The MLE for the
log OR for association parameter is
βˆ1 = log
(
Nˆ11 + 2Nˆ12
)
Nˆ01(
Nˆ11 + 2Nˆ10
)
2Nˆ02
,
where again Nˆ00 = N0 (1− pˆa)2, Nˆ01 = 2N0pˆa (1− pˆa), Nˆ02 = N0pˆ2a and Nˆ10, Nˆ11, Nˆ12
are the inverse probability weighted counts, with Nˆ10 = n10/qˆ0, Nˆ11 = n11/qˆ1, and
Nˆ12 = n12/qˆ2 (See Appendix). The MLEs for the three survival probabilities take the
following forms,
qˆ0 =
n10
N1 (1− pˆ∗a)2
, qˆ1 =
n11
2N1pˆ∗a (1− pˆ∗a)
and qˆ2 =
n12
N1 (pˆ∗a)
2 ,
where pˆ∗a, the estimated allele prevalence among affected individuals, takes the form
pˆ∗a =
2Ma+n11+2n12
2N1
. For the three scenarios to be described below, Ma and the MAF pˆa
will take different forms and be defined differently. Note that Ma is not a parameter
but an intermediate expression to represent half the estimated total number of copies
of a in the ungenotyped cases, i.e. the part in pˆ∗a that differs among the three scenarios.
Later in this section we will give an intuitive explanation for Ma and pˆ
∗
a. The scenarios
considered in sections 5.2.1 and 5.2.1 are special cases of that in section 5.2.1.
The General Mixed Scenario
We first consider a design where a representative sample of deceased cases has either
a spouse or child or both available for genotyping. Let mo denote the number of
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deceased cases who do not have child genotype data available. Let m1A (m1a) be the
number of deceased cases for whom we have a genotyped child and who must have
passed allele A (a) to the child, m1Aa be the number of deceased cases for whom we
have a genotyped child and the child has genotype Aa, m1∗ be the number of deceased
cases whose family members genotypes provide no information in predicting cases
genotype. These counts are calculated as m1A = m00 +m01 +m12 +m0c = m0+ +m12,
m1a = m10 +m21 +m22 +m2c = m10 +m2+, m1Aa = m1c, and m1∗ = m11 +mo. Then
Ma defined above is the positive solution of the following quadratic function, which
is obtained directly by solving the likelihood score equation (See Appendix):
1− 2pa
pa
(m−m1∗)M2a+m
[
m−m1∗ −m1Aa − 1− 2pa
pa
(m1a +m1Aa)
]
Ma−m2m1a = 0.
There is no closed-form solution for the MAF pa. Therefore we obtained the profile
likelihood for pa based on the closed forms of qˆ0, qˆ1, qˆ2, and βˆ1, and maximized it
numerically. We note that under our assumptions the spouses genotype alone does
not provide any information for predicting the deceased cases genotype. But because
of the correlation between parental genotypes conditional on the childs genotype,
incorporating the spouse genotype data should increase the precision of estimating
both the association parameter β1 (through more precise estimation of pa) and the
survival probabilities. We note that sections 5.2.1 and 5.2.1 are both special cases
of the general scenario. When for every deceased case only one child is recruited,
mjk = 0 for all j and k. When for every deceased case both the spouse and one child
are recruited, mjc = 0 for all j.
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The One Child and the Spouse Scenario
Under this scenario, we assume that genotype data for one child and the spouse are
available for all or a representative sample of the deceased case. We calculated Ma
and derived the MAF estimate pˆa as:
Ma = m
m0+ +m12
m−m11 , pˆa =
N01 + 2N02 +m1p + 2m2p
2(N0 +m)
.
Here m1p and m2p are the numbers of deceased cases who have spouse genotype Aa
and aa, respectively. Note that the MAF estimate pˆa uses data for both controls and
spouses of the deceased cases. This is because the spouses do not have the disease
and can be treated as an independent source of data for estimating the MAF.
The terms Ma and pˆ
∗
a have intuitive interpretations. For the m2+ deceased cases
whose childs genotype is aa and m10 cases whose child has genotype Aa and spouse
has genotype AA, each must have passed an ”a” allele to the child. Similarly, for
the m0+ deceased cases whose child’s genotype is AA and m12 cases whose child has
genotype Aa and spouse has genotype aa, each must have passed an ”A” allele to the
child. Thus there are m2+ +m10 and m0+ +m12 deceased cases who passed a and A
to the offspring, respectively. Note that m −m11 = m2+ + m10 + m0+ + m12. Since
”A” and ”a” have equal probability to be transmitted from a heterozygous parent to
his/her child, the total number of deceased cases who have passed ”a” alleles can be
estimated as mm0++m12
m−m11 , which is Ma. The number of surviving cases who have passed
a alleles to the offspring is estimated as n11
2
+ n12. Then the estimated total number
of cases passing a alleles to their offspring isMa +
n11
2
+ n12. Define the estimated
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MAF among cases as pˆ∗a = pˆ(a|Y = 1) then
pˆ∗a =
Ma +
n11
2
+ n12
N1
=
2Ma + n11 + 2n12
2N1
.
Note that pˆ∗a is a consistent estimator for the MAF in the case population also because
the genotype in the case population conforms to HWE under the log-additive model.
One Child Only Scenario
We next consider a design where a representative sample of cases has a child available
for genotyping and spouses are not genotyped. Sometimes it may be feasible to obtain
genotype data only for offspring, but not spouses. Let m0c, m1c, m2c be the respective
number of children with genotype AA, Aa, aa, and mo = m − m+c the number of
deceased cases without child genotype data.In this case, Ma is the positive solution
of the following quadratic equation:
1− 2pa
pa
(m−mo)M2a +m
[
m0c +m2c − 1− 2pa
pa
(m2c +m1c)
]
Ma −m2m2c = 0.
No closed form estimate exists for the MAF. Therefore we obtained the profile like-
lihood for pa, which is a function of the closed-form estimates qˆ0, qˆ1, qˆ2, and βˆ1, and
maximized it numerically as for the general scenario. We note that sections 5.2.1
and 5.2.1 are both special cases of this mixed scenario. When only one child is re-
cruited for each deceased case, mjp = 0 for all j. When both the spouse and one child
are recruited for each deceased case, mjc = 0 for all j.
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5.2.2. Use of Dominant Coding for Both Association and Survival
We next consider the use of a dominant model for survival. This version may be
needed in situations, e.g., if the frequency of the minor allele under study is low,
where a co-dominant model for survival becomes impractical due to sparse data and
more parsimonious models become necessary. With a dominant model for both asso-
ciation and survival, the MLEs are calculated similarly as in section 5.2.1 as follows.
For all the three scenarios considered in section 5.2.1, the estimated OR association
parameter takes the form
βˆ1 = log
(
Nˆ11 + Nˆ12
)
Nˆ00(
Nˆ01 + Nˆ02
)
Nˆ10
,
where Nˆ00, Nˆ01, and Nˆ02 are the predicted genotype counts in controls under HWE
as described previously,
Nˆ10 = N1 (1− pˆ∗∗a ) , Nˆ11 = N1pˆ∗∗a
n11
n11 + n12
, Nˆ12 = N1pˆ
∗∗
a
n12
n11 + n12
.
Here pˆ∗∗a =
(2−pˆa)Ma+n11+n12
N1
, and Ma takes the same forms for the three scenarios as in
section 5.2.1, 5.2.1 and 5.2.1, respectively. Note that Ma has the same interpretation
as in 5.2.1. Then (2− pˆa)Ma can be interpreted as the estimated number of deceased
cases who have at least one copy of the minor allele. Since n11 + n12 is number of
survived cases who have minor allele(s), pˆ∗∗a is the estimated proportion of cases who
carry the minor allele(s). Under this dominant model, we obtained pˆa based on its
profile likelihood.
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5.2.3. Extension of the Above Results for Assessing G− E Interactions.
The estimation and testing of multiplicative G − E interaction effects will also be
subject to survival bias. Suppose that a binary exposure E influences the occurrence
of disease and might also influence survival conditional on disease. We assume E
is available for all N0 + N1 study participants, regardless of availability of genotype
data. If survival is multiplicative in E effects and G effects, and if both survival
and association depend on the same binary coding for G or the association model
(but not the survival model) depends on co-dominant coding for G, then the na¨ıve
estimate of the multiplicative G−E interaction OR parameter from standard logistic
regression analysis and the accompanying standard error estimate are valid according
to theoretical results for two-phase studies (Breslow and Cain, 1988). Of course the
na¨ıve main-effect OR estimates for G and for E would likely be biased. On the other
hand, if survival depending on G follows a co-dominant model and the occurrence
of disease depends on G through a log-additive model, then na¨ıve estimates of both
the main and interaction effect OR parameters would likely be biased. The methods
in the first two subsections can be extended to obtain consistent estimates of all OR
parameters. Consider a simple logistic regression model for disease occurrence that
quantifies the joint effect of a di-allelic SNP and a binary environmental variable:
p(Y = 1|G,E) = e
β0+βgf(G)+βeE+βIf(G)×E
1 + eβ0+βgf(G)+βeE+βIf(G)×E
,
where f(G) is defined as in Equation (1), and E takes the value 1 or 0. Let Nijk
denote the total number of subjects with Y = i(i = 0, 1), G = j(j = 0, 1, 2), and
E = k(k = 0, 1). Let Nˆ1jk be the ”predicted number” of cases defined as above
through inverse probability weighting. Under the assumptions of G/E independence
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and HWE in the source population, and initially assuming that survival depends only
on G and not on E, we derived estimates of all association parameters. Note, however,
that G/E independence is only assumed here for convenience of demonstrating our
method and not needed for our general proposed design. If f(G) expresses log-
additive coding and h(G) co-dominant coding, we obtain the same estimates as those
in Section 5.2.1 for the population MAF pa and the survival probabilities (q0, q1, q2)
and
eβˆe =
Nˆ1+0N0+0
(
Nˆ111 + 2Nˆ101
)2
Nˆ1+1N0+1
(
Nˆ110 + 2Nˆ100
)2 , eβˆg = (1− pˆa)
(
Nˆ110 + 2Nˆ120
)
pˆa
(
Nˆ110 + 2Nˆ100
) ,
eβˆI =
(
Nˆ110 + 2Nˆ100
)(
Nˆ111 + 2Nˆ121
)
(
Nˆ111 + 2Nˆ101
)(
Nˆ110 + 2Nˆ120
) .
Under a dominant model for both f(G) and h(G), estimates of (q0, q1, q2) are the
same as those in Section 5.2.2, and the estimates of the OR parameters are
eβˆe =
N0+0Nˆ101
N0+1Nˆ100
, eβˆg =
(1− pˆa)2
(
Nˆ110 + Nˆ120
)
pˆa (2− pˆa) Nˆ100
, eβˆI =
Nˆ100
(
Nˆ111 + Nˆ121
)
Nˆ101
(
Nˆ110 + 2Nˆ120
) .
The two interaction parameter estimates above only involve data for cases and their
families and reduce to case-only estimates (Piegorsch, Weinberg, and Taylor, 1994)
under G/E independence and in the absence of survival bias. The association param-
eter estimators resemble those derived in Chen et al., 2012 in the absence of survival
bias, except that the observed counts in cases are replaced by the estimated counts
obtained through inverse-probability weighting. Similar results can be obtained when
survival depends on E both through its main effect and interaction with h(G), where
survival probabilities at each G/E combination need to be estimated.
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5.3. Simulation Study
We performed numerical studies to evaluate the performance of the proposed methods
in realistic scenarios for assessing marginal effects of G. Imposing our rare phenotype
assumption, we generated SNP genotypes for controls under HWE, and for cases from
the derived distribution
p(G|Y = 1) = e
βf(G)p(G|Y = 0)∑
G e
βf(G)p(G|Y = 0) ,
where the coding we impose is either log-additive, f(G) = the number of copies of the
minor allele, or dominant, f(G) = I(number of copies of the minor allele > 0). We
generated the indicator for failure to survival, S = 0, from the mixture distribution
p(S = 0|G, Y = 1) = ρ+ (1− ρ) eh(G)
1+eh(G)
.
Note that we do not fit this mixture distribution directly but make use here of the
fact that without knowing the true missing mechanism, we are still able to obtain
unbiased estimates of the survival probabilities and disease odds ratios as long as
probabilities of survival are allowed to be different for people with different genotypes.
We used a log-additive h(G) = α0 + α1G when generating S but fitted the less
restrictive co-dominant model for h(G) when the association model was log-additive,
and used dominant coding for both fitting and generating S when the true association
model was dominant. We refer to eα1 as the ”OR for death” below. Thus the true
p(S = 0|G, Y = 1) depends on G in a co-dominant or dominant fashion. Cases with
S = 0 were treated as ”deceased” in the analysis. We used random survival as the
gold standard for comparison, which was generated by setting α1 = 0. Then we
generated two separated indicator variables Rc and Rp for the general scenario from
the models p(Rc = 1|S = 0, G, Y = 1) = γc and p(Rp = 1|S = 0, G, Y = 1) = γp,
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where Rc = 1 and Rp = 1 indicated that the genotype data was available for the child
and spouse. Similarly, for the child/spouse scenario, genotype data for the child and
spouse are available as a pair, and we generated only one recruiting indicator R from
p(R = 1|S = 0, G, Y = 1) = γ. For the child only scenario, we generated indicator Rc
from p(Rc = 1|S = 0, G, Y = 1) = γc. Below we refer to γc, γp, and γ as ”recruiting
probabilities”.
In all simulations, we generated data for 500 cases (N1) and 500 controls (N0), where
genotype data for cases were treated as unavailable with probability p(S = 0|G, Y =
1), and genotype data for family members of deceased cases were assumed to be
available with probability γ or (γc, γp). We used a MAF of 0.2 and for α0 a value
-2.0, and each selected scenario was simulated 5,000 times.
Table 5.1 presents results showing the magnitude of survival bias for an analysis that
simply excludes data for deceased cases, based on 5,000 simulations. When the tested
variant was independent of or only modestly associated with death (eα1 <1.4), the
bias in estimation was small, and the type I error rates were close to the nominal 0.05
level. When the variant was more strongly associated with death, the type I error rate
became notably inflated. When only 30% of the missing genotype data were missing
due to reasons not related to G and 70% were missing due to G-related causes, with
the OR for death being 2.0, the missing genotype data rates corresponding to the three
genotypes AA, Aa, and aa were 0.38, 0.45, and 0.55 respectively. The observed type I
error rate corresponding to a nominal 0.05 was 0.110 when deceased cases were na¨ıvely
ignored in standard likelihood ratio tests of association. In general, the bias in the
na¨ıve estimation of the association OR parameter was small. For example, the mean
estimate was 1.58 when the true value for association was 1.8 and the OR for death
(eα1) was 2.0 (data not shown). Similar observations were made when a dominant
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Table 5.2: Parameter Estimation under Different Models and Scenarios for Genotyp-
ing Family Members of Deceased Cases.
2 
 
Table 2.  Parameter Estimation under Different Models and Scenarios for Genotyping 
Family Members of Deceased Cases. 
Model 
Odds 
Ratio
a
 
γb 
Estimates (S.D.) 
Mixed Child + Spouse Child Only 
Log-additive 
for 
association 
and 
co-dominant 
for survival 
log(1) 
= 0 
1 -0.002 (0.120) -0.004 (0.120) -0.005 (0.162) 
0.7 -0.002 (0.140) -0.004 (0.132) -0.002 (0.175) 
0.5 -0.004 (0.163) -0.002 (0.146) -0.009 (0.192) 
0
c
 -0.051 (0.130) 
log(1.4) 
= 0.336 
1 0.336 (0.113) 0.334 (0.113) 0.340 (0.147) 
0.7 0.335 (0.131) 0.339 (0.124) 0.335 (0.158) 
0.5 0.333 (0.151) 0.336 (0.136) 0.337 (0.172) 
0
c
 0.286 (0.123) 
log(1.8) 
= 0.588 
1 0.588 (0.109) 0.589 (0.109) 0.589 (0.139) 
0.7 0.583 (0.126) 0.588 (0.119) 0.587 (0.149) 
0.5 0.585 (0.144) 0.585 (0.131) 0.583 (0.162) 
 0
c
 0.539 (0.120) 
Dominant 
for both 
association 
and 
survival 
log(1) 
 = 0 
1 0.000 (0.143) 0.001 (0.143) 0.001 (0.193) 
0.7 0.004 (0.169) -0.004 (0.159) 0.002 (0.210) 
0.5 -0.002 (0.197) -0.003 (0.176) -0.001 (0.231) 
0
c
 -0.046 (0.148) 
log(1.4) 
= 0.336 
1 0.340 (0.143) 0.337 (0.143) 0.336 (0.188) 
0.7 0.336 (0.168) 0.336 (0.158) 0.337 (0.204) 
0.5 0.338 (0.195) 0.337 (0.176) 0.338 (0.224) 
0
c
 0.291 (0.144) 
log(1.8) 
= 0.588 
1 0.590 (0.145) 0.590 (0.145) 0.591 (0.187) 
0.7 0.589 (0.170) 0.592 (0.161) 0.589 (0.204) 
0.5 0.592 (0.197) 0.594 (0.179) 0.586 (0.224) 
 0
c
 0.546 (0.143) 
a: The odds ratio of association.  
b: Recruiting probability for family members. 
*Sample size is 500 for cases and 500 for controls; ρ = 0.3, 
0
2   , and 1 1 .4e

   (with survival probabilities 0.62, 
0.59 and 0.55 for each genotype. 
  
a: The odds ratio of assciation model.
b: Recruiting probability for family members.
c: The na¨ıve approach where no family members are recruited.
Sample size is 500 for cases and 500 for controls; ρ = 0.3, α0 = −2, and eα1
= 1.4 (with survival probabilities 0.62, 0.59 and 0.55 for each genotype).
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Figure 5.1: Power Plot.
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a. Log-additive model for association and co-dominant for survival, recruiting probability = 1;
b. Log-additive model for association and co-dominant for survival, recruiting probability = 0.7;
c. Log-additive model for association and co-dominant for survival, recruiting probability = 0.5;
d. Dominant model for both association and survival, recruiting probability = 1;
e. Dominant model for both association and survival, recruiting probability = 0.7;
f. Dominant model for both association and survival, recruiting probability = 0.5.
model was adopted for both survival and association (with the data simulation and the
analytic models corresponding). Table 5.2 presents the average log OR estimates and
the estimated standard deviations. The average estimates obtained by our method
were close to the true value. As expected, the child and spouse scenario resulted in
the lowest standard deviations, while the child-only scenario had the highest standard
deviations. The estimates without accounting for survival (rows Na¨ıve) appeared to
be biased, but the bias was small.
Figure 4.1 displays the powers under different models, scenarios and recruiting prob-
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abilities. In both the general mixed (Mixed) and child and spouse (Child+Spouse)
scenarios, the recruiting probabilities for children and spouses were assumed to be
1, 0.7 or 0.5. In the child-only (Child) scenario, children had recruiting probabilities
1, 0.7 or 0.5. Except for the three scenarios in sections 2.1, we considered two addi-
tional scenarios: the ideal one where all cases survived, and the general mixed scenario
where the recruiting probability of spouses was half of that of children (Mixed less
Spouse). That is, when the recruiting probabilities γc children were assumed to be 1,
0.7 or 0.5, the corresponding recruiting probabilities for spouses γp were 0.5, 0.35, and
0.25, respectively. The power appeared to be in increasing order from Child-Only,
Mixed lessSpouse, Mixed, Child + Spouse to Ideal. When the recruiting probability
was 1 in the log-additive model, the powers of both the Mixed and Child + Spouse
scenarios were close to the ideal. Not surprisingly, the power of all scenarios decreased
with decreasing recruiting probabilities. For example, under the model of log-additive
coding for association (odds ratio 1.4) and co-dominant coding for survival, in the
Mixed scenario, the powers corresponding to recruiting probabilities 1, 0.7 and 0.5
were 0.848, 0.723 and 0.606, respectively.
Interestingly, although the spouse genotype itself provides no information in pre-
dicting the cases genotype, inclusion of spouses can improve the power noticeably
together with the child genotype. Consider testing the association of a SNP under
the log-additive coding with OR 1.4. Consider that genotype data is available for
500 controls and that the survival probabilities are 0.62, 0.59 and 0.55 for cases with
genotype AA, Aa, and aa respectively. Assume that genotype data are also available
for family members of 70% of deceased cases. If 70% of children of the deceased
cases provided genotype information, the power was 0.565. If 70% of spouses of the
deceased cases were also randomly available, then on average, about half (49%) of the
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deceased cases have both children and spouses genotype. The study power under this
setting was 0.723. If genotype data were jointly available for the child and spouse as
a pair for 70% of the deceased cases, the study power increased to 0.782. A natural
question that arises under a fixed budget is: which one, recruiting x children or x/2
Child + Spouse pairs, would yield higher study power? As stated previously, the
power was 0.565 with genotype data for 70% children. The power increased to 0.595
with genotype data for 35% child and spouse pairs. Similarly, compared to the power
0.640 when genotyping only children of all the deceased cases, genotyping both the
child and the spouse of half of the deceased cases yielded higher power, 0.682.
Even when survival was independent ofG but the possible dependence of survival onG
was nevertheless modeled, our design achieved an increase in power by incorporating
family genotype data and applying the HWE constraint, partly through the improved
estimation of the MAF. With β1 = ln(1.2) and β1 = ln(1.4) (data not shown),
the power by the likelihood ratio test based on standard logistic regression with
surviving cases only was 0.322 and 0.792, respectively, which are lower than those
with the proposed method, 0.356 and 0.853. When both models were dominant, the
corresponding powers were 0.247 and 0.658 versus 0.257 and 0.676, respectively.
5.4. More Complex Family Structures
While we have evaluated the performance of our proposed methods in specific scenar-
ios where a child, the spouse, or a spouse/child pair were available, in many realistic
settings some deceased cases may not have a child available for genotyping but might
have one or both parents available, while still others might provide a sibling, a child,
or maybe a child and one parent. Under HWE and standard Mendelian transmission,
the Expectation-Maximization (EM) algorithm (Dempster, Laird, and Rubin, 1977)
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can be used to handle missing case genotypes under diverse family structures. Web
Appendix Table 5.2 shows two multinomial distributions, one for case families and
a hypothetical one for control families, again imposing a rare disease assumption so
that the control distribution only depends on the MAF. The parameter α here is a
normalizing constant to make the probabilities in the case sub-table sum to 1.0. All
controls have family genotypes that are not needed and therefore set to missing by
study design. Deceased cases have some family member genotypes that are known but
their own genotypes are missing. Thus this table represents the pseudo-complete data
likelihood for the case-control study we have considered above, and the observed-data
likelihood can be maximized by use of the EM algorithm. If instead some cases have
parental genotypes available in place of genotypes for a spouse and offspring, then
the multinomial is simply further split, to allow more cells, again applying Mendels
law. In the E-step, each deceased case is partitioned into possible corresponding
family cells by applying conditional cell probabilities based on the current parameter
estimates. The M-step then simply maximizes the corresponding log-linear likelihood
using standard software. EM iterations continue to convergence, and the likelihood
ratio test of association can be carried out by comparing the log of the maximized
observed data likelihood with that for a reduced model. Confidence intervals can also
be constructed based on maximizing profile likelihoods. Further extensions can en-
able the inclusion of covariates in the association model, under the weak assumption
that conditional on the observed genotypes of family members the missing genotype
does not depend on the covariates.
5.5. Discussion
The proposed design provides a useful approach for assessing and correcting survival
bias in case-control genetic association studies and improving power by enrolling
86
offspring and spouses of deceased cases and making proxy use of their genotypes.
The approach performed well for assessing both marginal genetic effects and gene-
environment (G − E) interactions (unreported simulation results). It also yields
unbiased estimates of association parameters for survival (data not shown). In ad-
dition to HWE, we make the usual assumptions that cases and controls are drawn
from the same source population and that the disease is rare. The current exposi-
tion considers a single di-allelic SNP in relation to association and survival and the
same study design can be extended to study multiple genetic and environmental fac-
tors, through application of the EM algorithm. Our approach introduces a useful
solution to a thorny non-ignorable missingness problem. Because it is based on a
retrospective likelihood, mis-specification of the nuisance survival model may lead to
biased estimates and inflated type-I error rate (see Appendix Table B.15). Therefore,
a co-dominant model, which is always a correct model, should be fitted for survival
whenever the data allows. We fit the log-additive or dominant model for survival
only when the data is too sparse, i.e, the number of subjects for a genotype category
is too small to fit a co-dominant model.
The family-supplemented design does have some limitations. Because of identifiability
issues one cannot use co-dominant models for both association and survival. The
identifiability issue can presumably be resolved if genotype data is available for a
random subset of deceased cases, but the issue cannot be addressed by genotyping
family members or obtaining richer marker genotype data. It is desirable to consider
other design options to address this challenge. In addition, extending our proposed
method to incorporate the survival time of the deceased cases may also be helpful.
As is true generally for case-control genetic analyses, our method requires that there
be no population stratification. We also implicitly assume there is no assortative mat-
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ing related to the SNP under study and that the SNP is not related to fertility (i.e.
the availability of a child to serve as a genetic proxy). However, we expect that a more
robust approach can be devised for settings where there may be population stratifi-
cation, using genetic control for population stratification, if we can approximate that
the population that cases and controls are sampled from contains a finite number
of discrete strata (e.g., Satten, Flanders, and Yang, 2001) and HWE holds within
each stratum. Ancestry informative markers would need to be obtained for con-
trols, live cases, and family members of deceased cases. Joint inference of association
parameters, survival probabilities, stratum membership, and minor allele frequency
(MAF) within each stratum would be needed. This task, at least computationally, is
nontrivial and worth investigating in future research.
We focused the theory of our method on the scenario where genotype data can be
made available for one child and/or the spouse for each deceased case in a represen-
tative subsample. But the method is readily extensible to include multiple children
with or without the spouse. If the number of family members recruited for each de-
ceased case is specified a priori, then a relevant question is which family members are
the most informative if they are equally recruitable. Clearly the spouse alone would
not be very informative, whereas a single offspring alone would provide somewhat
limited but informative genotype data as shown in the table and in the numerical
studies. Other choices are not so clear. Consider two children versus one child and
the spouse. When the two children have genotypes AA and aa, one can infer that the
genotype for both parents is Aa. But other combinations of the genotypes may not
be as informative as the same combination for one child and spouse (for example, if
the two children have the same genotype). In some circumstances a priori knowledge
of the biology might need to be considered. For example, if the gene under study
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may be related to longevity, the availability of the spouse may itself be selective, and
children might be preferred for that reason. Nevertheless, we explored the most plau-
sible scenarios in our theoretical and numerical studies, as recruitment of multiple
children for a case may be practically challenging even if it were more efficient.
For conditions with young age at onset, such as birth defects, children and spouses
will not be available at all and one would need to use the parents or siblings of cases
as genetic informants. The genotypes of deceased (or therapeutically aborted) cases
then become missing data and amenable to likelihood methods for estimation and
testing through the EM algorithm.
We have focused on genotype data for a single SNP at a time. But genotype data
at nearby markers could be helpful for infering the unobserved genotype data at that
SNP and could usefully be incorporated into the likelihood analysis (Lin et al., 2013).
Consider another SNP with alleles B and b that is so close to our SNP of interest
(that has alleles A and a) that the probability of recombination from parent to child
(i.e. in a single meiosis) can be taken to be 0. Suppose the case had a child with
genotypes Aa/Bb and spouse Aa/BB at the two loci. The child must carry either
haplotypes AB and ab or haplotypes Ab and aB, while the spouse carries haplotypes
AB and aB. The child must have inherited either AB or aB from the spouse. If Ab
does not exist in the population, the case must have a copy of haplotype ab. Without
genotype data for the second locus, the child and spouse genotype at the first locus,
Aa/Aa, are less informative for the missing parent cases genotype. Presumably, again
the EM algorithm could be used to take advantage of the LD structure in the genome
in imputing missing genotypes, though the details are beyond our present scope.
In conclusion, when studying the role of genetics in causing a disease that can be
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fatal, survival bias can result in nonignorable missingness of genotype information.
Under plausible assumptions, the genotyping of family members of deceased cases
can both correct that bias and improve power for detecting genetic associations. Our
methods are simple to implement and therefore can be applied to analyze genomewide
association studies. Software for implementing this method is available from the
authors upon request.
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CHAPTER 6
Conclusion
91
In this disseration, we developed statistical measures for quantifying predictive accu-
racy of cancer absolute risk prediction models, and proposed a novel semiparametric
maximum likelihood approach that accommodates incomplete predictor data under
rare disease approximation for the estimation of odds ratio parameters and the distri-
bution of candidate predictors. We then applied the statistical methods to evaluate
the added value of percent mammographic density and breast cancer risk SNPs in
breast cacner absolute risk projection. The semiparametric MLE approach was also
employed in a family-supplemented study design that we established to address sur-
vival bias in case-control genetic association studies.
These methods although have their own limitations as described in each chapter,
they are readily applicable to cancer risk projection problems in predictive accuracy
evaluation, efficient odds ratio estimation when new predictor has missing data, and
predictor distribution estimation when cohort data may not be available.
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APPENDIX A
Theoretical Derivations
A.1. Chapter 3
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A.1.1. Obtain the profile likelihood
We first maximize l(β,θ, δ) only with respect to δ with constraint
∑
j,l δjla = 1.
Using Lagrangian Multiplier method, the new function to be maximized is
Λ(β,θ, δ, λ) = l(β,θ, δ) + λ
(
1−
∑
j,l
δjla
)
.
The first derivatives of Λ(β,θ, δ, λ) with respect to δjla and λ are
∂Λ(β, θ, δ, λ)
∂δjla
=
njla
δjla
− n1a
∑
Z e
βTx xj+βssl+βzZpθ(Z|xj, sl, A ∈ Ia;Y = 0)∑
j,l
∑
Z e
βTx xj+βssl+βzZpθ(Z|xj, sl, A ∈ Ia;Y = 0)δjla
− λ,
∂Λ(β, θ, δ, λ)
∂λ
= 1−
∑
j,l
δjla.
Set them to 0 and solve for δjla. We have
δˆjla =
njla
n0a + µa
∑
Z e
βTx xj+βssl+βzZpθ(Z|xj, sl, A ∈ Ia;Y = 0)
,
where µa = n1a
{∑
j,l
∑
Z e
βTx xj+βssl+βzZpθ(Z|xj, sl, A ∈ Ia;Y = 0)δjla
}−1
. Instead of
estimating a large number of δjla’s, now we introduce new parameters µa’s to the
log-likelihood function. Let µ denote the vector of µa. Thus the profile log-likelihood
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function is
`p(β,θ,µ) =
m1+m0∑
i=1
log
{
eYi(β
T
xXi+βsSi+βzZi)pθ(Z|Xi, Si, Ai;Y = 0)
}
+
n1∑
i=m1+1
log
{∑
Z
eβ
T
xXi+βsSi+βzZpθ(Z|Xi, Si, Ai;Y = 0)
}
−
∑
jla
njla log
{
n0a + µa
∑
Z
eβ
T
x xj+βssl+βzZpθ(Z|xj, sl, A ∈ Ia;Y = 0)
}
+
∑
a
n1a log µa +
∑
jla
njla log njla −
∑
a
n1a log n1a.
Another way to express the profile log-likelihood function is to set
µa =
∑
j,l
∑
Z
eβ
T
x xj+βssl+βzZpθ(Z|xj, sl, A ∈ Ia;Y = 0)δjla.
Then
δˆjla =
njlaµa
n0aµa + n1a
∑
Z e
βTx xj+βssl+βzZpθ(Z|xj, sl, A ∈ Ia;Y = 0)
.
And `p(β,θ,µ)
==
m1+m0∑
i=1
log
{
eYi(β
T
xXi+βsSi+βzZi)pθ(Z|Xi, Si, Ai;Y = 0)
}
+
n1∑
i=m1+1
log
{∑
Z
eβ
T
xXi+βsSi+βzZpθ(Z|Xi, Si, Ai;Y = 0)
}
−
∑
jla
njla log
{
n0aµa + n1a
∑
Z
eβ
T
x xj+βssl+βzZpθ(Z|xj, sl, A ∈ Ia;Y = 0)
}
+
∑
a
n0a log µa +
∑
jla
njla log njla.
which directly gives the `p(β,θ,µ) in section 5.2.1.
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A.1.2. The new parameter µ
Let ψ = (β,θ). Since µ is a function of (β,θ), µ ≡ µψ. The score function of the
profile likelhood `p
(
ψ,µψ
)
is
˙`p
(
ψ,µψ
)
=
d`p
(
ψ,µψ
)
dψT
=
∂`p
(
ψ,µψ
)
∂ψT
+
∂`p
(
ψ,µψ
)
∂µT
∂µψ
∂ψT
.
Note that
∂`p(ψ,µψ)
∂µT
≡ 0 because µ was solved from the score equation of δ. Then an
important relationship to know is that
0 =
d
dψ
(
∂`p
(
ψ,µψ
)
∂µT
)
=
∂2`p
(
ψ,µψ
)
∂ψ∂µT
+
∂µTψ
∂ψ
∂2`p
(
ψ,µψ
)
∂µ∂µT
The information matrix of ψ is
I(ψ)µψ = −
d2`p
(
ψ,µψ
)
dψdψT
= −∂
2`p
(
ψ,µψ
)
∂ψ∂ψT
− ∂µ
T
ψ
∂ψ
∂2`p
(
ψ,µψ
)
∂µ∂ψT
− ∂
2`p
(
ψ,µψ
)
∂ψ∂µT
∂µψ
∂ψT
−∂µ
T
ψ
∂ψ
∂2`p
(
ψ,µψ
)
∂µ∂µT
∂µψ
∂ψT
.
If we treat µ as new parameters rather than functions of ψ, the information matrix
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of ψ can be obtained as
I(ψ)µ = −∂
2`p (ψ,µ)
∂ψ∂ψT
+
∂2`p (ψ,µ)
∂ψ∂µT
[
∂2`p (ψ,µ)
∂µ∂µT
]−1
∂2`p (ψ,µ)
∂µ∂ψT
.
The difference between I(ψ)µ and I(ψ)µψ is
I(ψ)µ − I(ψ)µψ
=
∂2`p (ψ,µ)
∂ψ∂µT
[
∂2`p (ψ,µ)
∂µ∂µT
]−1
∂2`p (ψ,µ)
∂µ∂ψT
+
∂µTψ
∂ψ
∂2`p
(
ψ,µψ
)
∂µ∂ψT
+
∂2`p
(
ψ,µψ
)
∂ψ∂µT
∂µψ
∂ψT
+
∂µTψ
∂ψ
∂2`p
(
ψ,µψ
)
∂µ∂µT
∂µψ
∂ψT
=
[
∂2`p
(
ψ,µψ
)
∂ψ∂µT
+
∂µTψ
∂ψ
∂2`p
(
ψ,µψ
)
∂µ∂µT
][
∂2`p
(
ψ,µψ
)
∂µ∂µT
]−1
×
[
∂2`p
(
ψ,µψ
)
∂µ∂ψT
+
∂2`p
(
ψ,µψ
)
∂µ∂µT
∂µψ
∂ψT
]
= 0.
The last equation holds because
∂2`p(ψ,µψ)
∂ψ∂µT
+
∂µTψ
∂ψ
∂2`p(ψ,µψ)
∂µ∂µT
= 0 as showed earlier.
Thus we have
I(ψ)µ = I(ψ)µψ .
A.1.3. Proof for asymptotic normality
∂`(ψ,µ)
∂ψ
=
[
∂`(β,θ,µ)
∂β
∂`(β,θ,µ)
∂θ
]T
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Denote Ri as the indicator whether a subject is sampled to phase II.
∂`(β,θ,µ)
∂β
=
n1∑
i=1
Ri

Xi
Si
Zi

+
n1∑
i=1
(1−Ri)
∑
Z e
(Xi Si Z)β(Xi Si Z)
Tpθ(Z|Xi, Si, Ai;Y = 0)∑
Z e
(Xi Si Z)βpθ(Z|Xi, Si, Ai;Y = 0)
−
∑
jla
njla
n1a
∑
Z e
(Xj Sl Z)β(Xj Sl Z)
Tpθ(Z|Xj, Sl, A ∈ Ia;Y = 0)
n0aµa + n1a
∑
Z e
(Xj Sl Z)βpθ(Z|Xj, Sl, A ∈ Ia;Y = 0)
Note that
pθ(Z|X,S,A;Y = 1) = e
(X S A)Tβpθ(Z|X,S,A;Y = 0)∑
Z e
(X S A)Tβpθ(Z|X,S,A;Y = 0)
which is the density function of Z given data in cases.
Then the second term fraction
∑
Z e
(Xi Si Z)β(Xi Si Z)
Tpθ(Z|Xi, Si, Ai;Y = 0)∑
Z e
(Xi Si Z)βpθ(Z|Xi, Si, Ai;Y = 0)
=
∑
Z

e(Xi Si Z)βpθ(Z|Xi, Si, Ai;Y = 0)∑
Z e
(Xi Si Z)βpθ(Z|Xi, Si, Ai;Y = 0)

Xi
Si
Z


=

Xi
Si∑
Z Zpθ(Z|Xi, Si, Ai;Y = 1)

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=
Xi
Si
E[Z|Xi, Si, Ai;Y = 1]

The numerator and denominator of the third term are divided by∑
Z e
(Xi Si Z)βpθ(Z|Xi, Si, Ai;Y = 0) in the same time. Note that µa divided by the
previous expression can be obtained from the calculation of profile liklihood (Section
6.1). Then the third term
∑
jla
njla
n1a
∑
Z e
(Xj Sl Z)β(Xj Sl Z)
Tpθ(Z|Xj, Sl, A ∈ Ia;Y = 0)
n0aµa + n1a
∑
Z e
(Xj Sl Z)βpθ(Z|Xj, Sl, A ∈ Ia;Y = 0)
=
∑
jla
njla
n1a (Xj Sl E[Z|Xj, Sl, A ∈ Ia;Y = 1])T
n0a
n1a
njla/δjla−n0a + n1a
=
∑
jla
njla

Xj
Sl
E[Z|Xj, Sl, A ∈ Ia;Y = 1]

(
1− n0aδjla
njla
)
=
n1+n0∑
i=1

Xi
Si
E[Z|Xi, Si, Ai;Y = 1]

−n0
∑
jla

Xj
Sl
E[Z|Xj, Sl, A ∈ Ia;Y = 1]
 p(A ∈ Ia|Y = 0)p(Xj, Sl|A ∈ Ia, Y = 0)
=
n1+n0∑
i=1

Xi
Si
E[Z|Xi, Si, Ai;Y = 1]

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−n0
n1+n0∑
i=1

Xi
Si
E[Z|Xi, Si, Ai;Y = 1]
 p(Xi, Si, Ai|Y = 0)
=
n1+n0∑
i=1

Xi
Si
E[Z|Xi, Si, Ai;Y = 1]
− n0E


Xi
Si
E[Z|Xi, Si, Ai;Y = 1]

∣∣∣∣∣∣∣∣∣∣
Y = 0

Then ∂`(β,θ,µ)
∂β
=
n1∑
i=1
Ri

Xi
Si
Zi
+
n1∑
i=1
(1−Ri)

Xi
Si
E[Z|Xi, Si, Ai;Y = 1]

−
n1∑
i=1

Xi
Si
E[Z|Xi, Si, Ai;Y = 1]
−
n1+n0∑
i=n1+1

Xi
Si
E[Z|Xi, Si, Ai;Y = 1]

+n0E


Xi
Si
E[Z|Xi, Si, Ai;Y = 1]

∣∣∣∣∣∣∣∣∣∣
Y = 0

=
n1∑
i=1
Ri


Xi
Si
Zi
−

Xi
Si
E[Z|Xi, Si, Ai;Y = 1]


−
n1+n0∑
i=n1+1


Xi
Si
E[Z|Xi, Si, Ai;Y = 1]
− E

Xi
Si
E[Z|Xi, Si, Ai;Y = 1]
∣∣∣∣∣∣∣∣∣∣
Y = 0


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∂`(β,θ,µ)
∂θ
=
n1+n0∑
i=1
Ri
p˙θ(Zi|Xi, Si, Ai;Y = 0)
pθ(Zi|Xi, Si, Ai;Y = 0)
+
n1∑
i=1
(1−Ri)
∑
Z e
(Xi Si Z)βp˙θ(Z|Xi, Si, Ai;Y = 0)∑
Z e
(Xi Si Z)βpθ(Z|Xi, Si, Ai;Y = 0)
−
∑
jla
njla
n1a
∑
Z e
(Xj Sl Z)βp˙θ(Z|Xj, Sl, A ∈ Ia;Y = 0)
n0aµa + n1a
∑
Z e
(Xj Sl Z)βpθ(Z|Xj, Sl, A ∈ Ia;Y = 0)
If we write p˙θ(Z|Xi, Si, Ai;Y = 0) as
p˙θ(Z|Xi, Si, Ai;Y = 0)
pθ(Z|Xi, Si, Ai;Y = 0)pθ(Z|Xi, Si, Ai;Y = 0),
we can treat p˙θ(Z|Xi,Si,Ai;Y=0)
pθ(Z|Xi,Si,Ai;Y=0) similarly as (Xi Si Z) in
∂`(β,θ,µ)
∂β
. Then ∂`(β,θ,µ)
∂θ
=
n1+n0∑
i=n1+1
Ri
p˙θ(Zi|Xi, Si, Ai;Y = 0)
pθ(Zi|Xi, Si, Ai;Y = 0)
+
n1∑
i=1
Ri
p˙θ(Zi|Xi, Si, Ai;Y = 0)
pθ(Zi|Xi, Si, Ai;Y = 0)
−
n1∑
i=1
RiE
[
p˙θ(Z|Xi, Si, Ai;Y = 0)
pθ(Z|Xi, Si, Ai;Y = 0)
∣∣∣∣Xi, Si, Ai, Y = 1]
−
n1+n0∑
i=n1+1
{
E
[
p˙θ(Z|Xi, Si, Ai;Y = 0)
pθ(Z|Xi, Si, Ai;Y = 0)
∣∣∣∣Xi, Si, Ai, Y = 1]}
+n0E
{
E
[
p˙θ(Z|Xi, Si, Ai;Y = 0)
pθ(Z|Xi, Si, Ai;Y = 0)
∣∣∣∣Xi, Si, Ai, Y = 1]∣∣∣∣Y = 0}
A.2. Chapter 5 Theoretical results
Here we present the derivation for the estimates under the log-additive coding for
association and co-dominant coding for survival, where β2 = 2β1. The estimates
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under the dominant model for both association and survival, and the model with
G − E interaction can be derived similarly and are not shown here. We will only
derive the estimates under the mixed scenario, while the child only and child +
spouse scenarios are simply special cases of the mixed scenario. The log-likelihood
function (3) can further written as `(β1, q, pa)
= n10 log q0 + n11 log q1 + n12 log q2 + (n11 + 2n12)β1
+m1A log
{
(1− q0)(1− pa) + (1− q1)eβ1pa
}
+m1a log
{
(1− q1)eβ1(1− pa) + (1− q2)e2β1pa
}
+m1Aa log
{
(1− q0)1− pa
2
+ (1− q1)eβ1 1
2
+ (1− q2)e2β1 pa
2
}
+m1∗ log
{
(1− q0)(1− pa)2 + (1− q1)eβ12pa(1− pa) + (1− q2)e2β1p2a
}
−N1 log
{
(1− pa)2 + eβ12pa(1− pa) + e2β1p2a
}
+(n11 + 2n12 +N01 + 2N02 +m01 +m12 +m22 +m1+ + 2m2+) log pa
+(2n10 + n11 + 2N00 +N01 +m00 +m10 +m21 + 2m0+ +m1+) log(1− pa)
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The score functions for the parameters are
(1)
∂`(β1, q, pa)
∂β1
= n11 + 2n12 +m1A
(1− q1)eβ1pa
X1A
+m1a
(1− q1)eβ1(1− pa) + 2(1− q2)e2β1pa
X1a
+m1Aa
(1− q1)eβ1 + 2(1− q2)e2β1pa
X1Aa
+m1∗
(1− q1)eβ12pa(1− pa) + 2(1− q2)e2β1p2a
X1∗
−N1 e
β12pa(1− pa) + 2e2β1p2a
X
,
(2)
∂`(β1, q, pa)
∂q0
=
n10
q0
+m1A
−(1− pa)
X1A
+m1a
0
X1a
+m1Aa
−(1− pa)
X1Aa
+m1∗
−(1− pa)2
X1∗
,
(3)
∂`(β1, q, pa)
∂q1
=
n11
q1
+m1A
−eβ1pa
X1A
+m1a
−eβ1(1− pa)
X1a
+m1Aa
−eβ1
X1Aa
+m1∗
−eβ12pa(1− pa)
X1∗
,
(4)
∂`(β1, q, pa)
∂q2
=
n12
q2
+m1A
0
X1A
+m1a
−e2β1pa
X1a
+m1Aa
−e2β1pa
X1Aa
+m1∗
−e2β1p2a
X1∗
,
(5)
∂`(β1, q, pa)
∂pa
= m1A
−(1− q0) + (1− q1)eβ1
X1A
+m1a
−(1− q1)eβ1 + (1− q2)e2β1
X1a
+m1Aa
−(1− q0) + (1− q2)e2β1
X1Aa
+m1∗
−2(1− q0)(1− pa) + (1− q1)eβ1(2− 4pa) + 2(1− q2)e2β1pa
X1∗
−N1−2(1− pa) + e
β1(2− 4pa) + 2e2β1pa
X
+
n11 + 2n12 +N01 + 2N02 +m01 +m12 +m22 +m1+ + 2m2+
pa
−2n10 + n11 + 2N00 +N01 +m00 +m10 +m21 + 2m0+ +m1+
1− pa ,
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where X1A = (1−q0)(1−pa)+(1−q1)eβ1pa, X1a = (1−q1)eβ1(1−pa)+(1−q2)e2β1pa,
X1Aa = (1− q0)(1− pa) + (1− q1)eβ1 + (1− q2)e2β1pa, X1∗ = (1− q0)(1− pa)2 + (1−
q1)e
β12pa(1− pa) + (1− q2)e2β1p2a and X = (1− pa)2 + eβ12pa(1− pa) + e2β1p2a.
Setting the five score functions to 0, we solve for the estimates with the following
steps. First, calculate (2)× (1− q0) + (3)× (1− q1) + (4)× (1− q2) and we have
n10
1− q0
q0
+ n11
1− q1
q1
+ n12
1− q2
q2
= m1A +m1a +m1Aa +m1∗ = m,
so that
n10
q0
+
n11
q1
+
n12
q2
= N1.
Then we calculate (1) + (3)× (1− q1) + (4)× 2(1− q2), we have
n11
q1
+ 2
n12
q2
= N1
eβ12pa(1− pa) + 2e2β1p2a
(1− pa)2 + eβ12pa(1− pa) + e2β1p2a
.
Solve this equation for eβ1 , we obtain
eβˆ1 =
n11/q1 + 2n12/q2
2n10/q0 + n11/q1
1− pa
pa
.
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By definition, n1j/pj is the estimated total number of cases with genotype j and
n1j
pj
= p(G = j|Y = 1)
=
p(G = j, Y = 1)∑
j=0,1,2 p(G = j, Y = 1)
=
ejβ1p(G = j|Y = 0)
p(G = 0|Y = 0) + eβ1p(G = 1|Y = 0) + e2β1p(G = 2|Y = 0)
=
ejβ1p(G = j|Y = 0)
(1− pa)2 + eβ12pa(1− pa) + e2β1p2a
=
ejβ1p(G = j|Y = 0)
[(1− pa) + eβ1pa]2
Then n10
q0
= N1
[
1− eβ1pa
(1−pa)+eβ1pa
]2
, n11
q1
= 2N1
[
1− eβ1pa
(1−pa)+eβ1pa
] [
eβ1pa
(1−pa)+eβ1pa
]
, and
n12
q2
= N1
[
eβ1pa
(1−pa)+eβ1pa
]2
. Let p∗a =
eβ1pa
(1−pa)+eβ1pa , then
q0 =
n10
(1− p∗a)2
, q1 =
n11
2p∗a(1− p∗a)
, q2 =
n12
(p∗a)2
, eβ1 =
p∗a
1− p∗a
1− pa
pa
.
Plug q0, q1, q2 and e
β1 , which are functions of p∗a and pa, into (2), we finally get
m1A
m−Ma +
m1Aa
m+ 1−2pa
pa
Ma
+
m1∗
m
= 1,
where Ma = N1p
∗
a − n10 − n11/2. Therefore
pˆ∗a =
Ma + n10 +
n11
2
N1
,
and Ma is the positive root of equation
1− 2pa
pa
(m−m1∗)M2a+m
[
m−m1∗ −m1Aa − 1− 2pa
pa
(m1a +m1Aa)
]
Ma−m2m1a = 0.
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With p∗a estimated, we now have closed form estimates for e
β1 , q0, q1 and q2 as
functions of pa. Then pa is obtained by maximizing its profile likelihood.
The derivation for estimates under the dominant coding for both association and
survival requires very similar techniques as we showed above.
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APPENDIX B
Appendix Tables
B.1. Chapter 2
Table B.1: Estimates of Z model Parameters in Real Data Analysis.
Parameters Estimates (S.D.) P Value 95% C.I.
Z Model
Mean
Parameters
Intercept 1.4754 (0.1836) 8.88E-16 (1.1155, 1.8353)
Ageflb 0.1571 (0.0330) 1.89E-06 (0.0925, 0.2217)
Agemen -0.1000 (0.0415) 1.60E-02 (-0.1814, -0.0186)
Nbiops 0.2345 (0.0448) 1.68E-07 (0.1467, 0.3224)
Weight -0.4120 (0.0322) 0.00E+00 (-0.4752, -0.3488)
Age -0.0308 (0.0031) 0.00E+00 (-0.0369, -0.0248)
Z Model
Variance
Parameters
Intercept 1.1450 (0.2493) 4.35E-06 (0.6565, 1.6335)
Weight -0.1514 (0.0435) 4.94E-04 (-0.2366, -0.0662)
Age 0.0099 (0.0043) 2.23E-02 (0.0014, 0.0185)
Zero Model ρ 0.1003 (0.0095) 0.00E+00 (0.0817, 0.1189)
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Table B.2: 74 SNPs from External Sources in Real Data Analysis.
SNP Locus Chr Alleles MAF Published OR 95% C.I.
ZNF365 10 G/A 0.16 0.86 (0.84, 0.88)
PTHLH 12 A/G 0.12 0.86 (0.83, 0.88)
2q35 2 A/G 0.47 0.88 (0.86, 0.90)
9q31 9 T/G 0.38 0.89 (0.88, 0.91)
ADAM29 4 C/A 0.13 0.90 (0.87, 0.92)
2q14.2 2 C/T 0.098 0.91 (0.88, 0.94)
8q21.11 8 T/G 0.18 0.91 (0.89, 0.93)
NTN4 12 A/G 0.30 0.91 (0.89, 0.93)
PDE4D 5 T/G 0.095 0.92 (0.89, 0.95)
12q24 12 A/G 0.42 0.92 (0.90, 0.94)
RAD51L1 14 C/T 0.23 0.92 (0.90, 0.94)
NRIP1 21 G/A 0.27 0.92 (0.90, 0.94)
PAX9 14 G/A 0.21 0.93 (0.91, 0.95)
FTO 16 T/G 0.40 0.93 (0.91, 0.95)
SSBP4 19 A/G 0.35 0.93 (0.91, 0.95)
PEX14 1 A/G 0.33 0.94 (0.92, 0.96)
CDCA7 2 A/G 0.16 0.94 (0.92, 0.97)
TERT 5 C/T 0.29 0.94 (0.92, 0.95)
FOXQ1 6 T/C 0.39 0.94 (0.92, 0.96)
7q35 7 G/A 0.25 0.94 (0.92, 0.96)
COX11 17 G/A 0.28 0.94 (0.92, 0.96)
2q31.1 2 G/A 0.48 0.95 (0.93, 0.97)
10q26.12 10 C/T 0.32 0.95 (0.93, 0.96)
11q13.1 11 G/T 0.47 0.95 (0.93, 0.96)
11q24.3 11 C/T 0.41 0.95 (0.93, 0.97)
18q11.2 18 G/C 0.38 0.95 (0.93, 0.97)
CHST9 18 T/G 0.40 0.96 (0.94, 0.98)
CASP8 2 C/G 0.13 0.97 (0.94, 1.00)
ANKRD16 10 C/T 0.44 0.98 (0.96, 1.00)
LGR6 1 G/A 0.41 1.00 (0.98, 1.02)
2p24.1 2 C/T 0.36 1.04 (1.01, 1.06)
FTO 16 T/A 0.24 1.04 (1.02, 1.06)
MERIT40 19 G/A 0.19 1.04 (1.01, 1.06)
TET2 4 C/T 0.23 1.05 (1.03, 1.08)
RAB3C 5 T/C 0.38 1.05 (1.03, 1.07)
RANBP1 6 A/G 0.43 1.05 (1.03, 1.07)
6q14.1 6 T/C 0.22 1.05 (1.03, 1.08)
12p13.1 12 G/C 0.26 1.05 (1.03, 1.07)
TGFBR2 3 G/C 0.35 1.06 (1.03, 1.08)
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SNP Locus Chr Alleles MAF Published OR 95% C.I.
TERT 5 C/T 0.26 1.06 (1.04, 1.09)
CDKN2A/B 9 G/T 0.17 1.06 (1.03, 1.08)
9q31.2 9 C/A 0.39 1.06 (1.03, 1.08)
TCF7L2 10 A/G 0.46 1.06 (1.04, 1.08)
CCDC88C 14 A/G 0.34 1.06 (1.04, 1.09)
19q13.31 19 G/A 0.46 1.06 (1.04, 1.08)
1p13.2 1 C/T 0.17 1.07 (1.04, 1.10)
3p26.2 3 A/G 0.40 1.07 (1.04, 1.09)
EBF1 5 T/C 0.43 1.07 (1.05, 1.09)
8p21.1 8 C/A 0.32 1.07 (1.05, 1.09)
8q24.21 8 C/T 0.16 1.07 (1.04, 1.10)
DNAJC1 10 G/A 0.29 1.07 (1.05, 1.09)
LSP1 11 T/C 0.31 1.07 (1.05, 1.09)
2q35 2 C/T 0.26 1.08 (1.06, 1.10)
ESR1 6 G/A 0.34 1.08 (1.06, 1.10)
ZMIZ1 10 C/T 0.38 1.08 (1.06, 1.10)
RAD51L1 14 C/T 0.16 1.08 (1.05, 1.11)
CDYL2 16 A/G 0.22 1.08 (1.05, 1.10)
1p11.2 1 A/G 0.40 1.09 (1.07, 1.11)
8q24 8 A/G 0.41 1.09 (1.07, 1.12)
SLC4A7 3 C/T 0.47 1.10 (1.08, 1.12)
MAP3K1 5 A/C 0.28 1.12 (1.10, 1.15)
22q12.2 22 T/C 0.036 1.12 (1.07, 1.18)
MKL1 22 T/C 0.11 1.12 (1.09, 1.16)
5p12 5 A/G 0.25 1.13 (1.10, 1.15)
HNF4G 8 A/G 0.07 1.13 (1.09, 1.17)
ESR1 6 G/A 0.07 1.16 (1.12, 1.21)
CCDN1 11 C/T 0.15 1.21 (1.18, 1.24)
TOX3 16 G/A 0.26 1.24 (1.21, 1.27)
DNAJC1 10 A/C 0.02 1.26 (1.18, 1.35)
BRCA2 13 A/T 0.008 1.26 (1.14, 1.39)
FGFR2 10 G/A 0.40 1.27 (1.24, 1.29)
FGFR2 10 G/A 0.40 1.27 (1.24, 1.29)
CCND1 11 A/C 0.06 1.31 (1.26, 1.36)
CCND1 11 C/G 0.12 1.33 (1.28, 1.37)
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Table B.3: Estimates of Predictive Accuracy Statistics with Absolute Risk Cutoff in
Real Data Analysis.
Statistics Model Risk Cutoff (S.D.) Estimates*
PPV (95%
risk)
BCRAT 0.0054 (0.0004) 0.0075 (0.0008)
BCRAT+PD+Weight 0.0071 (0.0013) 0.0093 (0.0014)
BCRAT+SNP 0.0070 (0.0007) 0.0093 (0.0007)
BCRAT+PD+Weight+SNP 0.0082 (0.0016) 0.0117 (0.0017)
AUC
BCRAT - 0.6073 (0.0110)
BCRAT+PD+Weight - 0.6588 (0.0119)
BCRAT+SNP - 0.6738 (0.0093)
BCRAT+PD+Weight+SNP - 0.7057 (0.0074)
PCF
(q=0.1)
BCRAT 0.0048 (0.0002) 0.2085 (0.0184)
BCRAT+PD+Weight 0.0056 (0.0002) 0.2575 (0.0149)
BCRAT+SNP 0.0056 (0.0001) 0.2537 (0.0064)
BCRAT+PD+Weight+SNP 0.0062 (0.0001) 0.2987 (0.0114)
PCF
(q=0.2)
BCRAT 0.0035 (0.0002) 0.3562 (0.0285)
BCRAT+PD+Weight 0.0044 (0.0001) 0.3997 (0.0181)
BCRAT+SNP 0.0043 (0.0000) 0.4131 (0.0082)
BCRAT+PD+Weight+SNP 0.0045 (0.0000) 0.4657 (0.0128)
PCF
(q=0.3)
BCRAT 0.0031 (0.0001) 0.4598 (0.0327)
BCRAT+PD+Weight 0.0036 (0.0001) 0.5239 (0.0188)
BCRAT+SNP 0.0035 (0.0000) 0.5405 (0.0091)
BCRAT+PD+Weight+SNP 0.0035 (0.0000) 0.5923 (0.0123)
PCF
(q=0.4)
BCRAT 0.0028 (0.0001) 0.7211 (0.0673)
BCRAT+PD+Weight 0.0031 (0.0001) 0.6297 (0.0177)
BCRAT+SNP 0.0030 (0.0000) 0.6470 (0.0098)
BCRAT+PD+Weight+SNP 0.0029 (0.0000) 0.6939 (0.0109)
*: Predictive accuracy statistics estimates with bootstrapping standard
deviations.
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Table B.4: Estimates of Z Model Parameters in Simulation with 2 SNPs (Moderate
Assocation).
Parameters True Estimatesa 95% C.I. Coverage
Z Model
Mean
Parameters
Ib 1.5 1.4986 (0.1460, 0.1525) (1.2125, 1.7848) 0.930
X1 0.15 0.1512 (0.0364, 0.0366) (0.0798, 0.2226) 0.938
X2 -0.1 -0.1027 (0.0463, 0.0464) (-0.1934, -0.0120) 0.945
X3 0.2 0.1997 (0.0395, 0.0390) (0.1222, 0.2771) 0.955
X4 0.05 0.0502 (0.0683, 0.0700) (-0.0837, 0.1841) 0.945
A -0.03 -0.0302 (0.0021, 0.0023) (-0.0344, -0.0260) 0.939
Z Model
Variance
Parameters
Ib 1.2 1.2071 (0.2336, 0.2406) (0.7492, 1.6649) 0.941
X1 -0.08 -0.0803 (0.0604, 0.0601) (-0.1986, 0.0381) 0.959
X2 -0.05 -0.0471 (0.0761, 0.0787) (-0.1963, 0.1021) 0.944
X3 0.1 0.0974 (0.0659, 0.0658) (-0.0318, 0.2265) 0.957
X4 0.05 0.0627 (0.1154, 0.1126) (-0.1635, 0.2888) 0.966
A 0.01 0.0102 (0.0035, 0.0036) (0.0034, 0.0170) 0.949
a: Parameter estimates with asymptotic standard deviations and empirical
standard deviations.
b: Intercept.
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Table B.5: Estimates of Predictive Accuracy Statistics with Absolute Risk Cutoff in
Simulation Studies with 2 SNPs.
Statistics Model Absolute Risk Cutoff (S.D.)
Weaka Moderateb Strongc
PPV
(95%
risk)
Model-XZ 0.0082 (0.0008) 0.0080 (0.0008) 0.0074 (0.0008)
Model-XZ-SNP 0.0082 (0.0007) 0.0096 (0.0004) 0.0116 (0.0003)
Model-XZ-SNPgs 0.0082 (0.0007) 0.0098 (0.0005) 0.0117 (0.0003)
PCF
(q=0.1)
Model-XZ 0.0062 (0.0004) 0.0061 (0.0004) 0.0058 (0.0004)
Model-XZ-SNP 0.0064 (0.0004) 0.0066 (0.0002) 0.0067 (0.0002)
Model-XZ-SNPgs 0.0064 (0.0004) 0.0067 (0.0002) 0.0063 (0.0003)
PCF
(q=0.2)
Model-XZ 0.0046 (0.0002) 0.0046 (0.0002) 0.0045 (0.0002)
Model-XZ-SNP 0.0046 (0.0001) 0.0043 (0.0001) 0.0034 (0.0002)
Model-XZ-SNPgs 0.0046 (0.0001) 0.0043 (0.0001) 0.0029 (0.0002)
PCF
(q=0.3)
Model-XZ 0.0036 (0.0001) 0.0036 (0.0001) 0.0036 (0.0001)
Model-XZ-SNP 0.0036 (0.0001) 0.0032 (0.0001) 0.0020 (0.0001)
Model-XZ-SNPgs 0.0036 (0.0001) 0.0032 (0.0001) 0.0017 (0.0002)
PCF
(q=0.4)
Model-XZ 0.0029 (0.0001) 0.0030 (0.0001) 0.0030 (0.0001)
Model-XZ-SNP 0.0029 (0.0001) 0.0025 (0.0001) 0.0014 (0.0001)
Model-XZ-SNPgs 0.0029 (0.0001) 0.0024 (0.0001) 0.0011 (0.0002)
a: True βw = (0.3,−0.15); b: True βw = (0.5, 1); c: True βw = (1, 2).
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Table B.6: Estimates of Z Model Parameters in Simulation with 74 SNPs.
Parameters True Estimatesa 95% C.I. Coverage
Z Model
Mean
Parameters
Ib 1.5 1.5342(0.1792, 0.1753) (1.1830, 1.8855) 0.949
X1 0.15 0.1452(0.0419, 0.0422) (0.0631, 0.2273) 0.948
X2 -0.1 -0.1048(0.0532, 0.0541) (-0.2091, -0.0005) 0.945
X3 0.2 0.1948(0.0450, 0.0465) (0.1067, 0.2829) 0.940
X4 0.05 0.0384(0.0783, 0.0802) (-0.1151, 0.1920) 0.944
S -0.4 -0.4036(0.0354, 0.0349) (-0.4731, -0.3342) 0.955
A -0.03 -0.0305(0.0024, 0.0025) (-0.0353, -0.0257) 0.943
Z Model
Variance
Parameters
Ib 1.2 1.1963(0.2541, 0.2545) (0.6983, 1.6942) 0.949
X1 -0.08 -0.0772(0.0601, 0.0601) (-0.1951, 0.0406) 0.953
X2 -0.05 -0.0453(0.0761, 0.0750) (-0.1943, 0.1038) 0.953
X3 0.1 0.1075(0.0658, 0.0674) (-0.0214, 0.2364) 0.945
X4 0.05 0.0682(0.1160, 0.1132) (-0.1592, 0.2955) 0.958
S -0.1 -0.0968(0.0496, 0.0501) (-0.1940, 0.0004) 0.942
A 0.01 0.0102(0.0034, 0.0034) (0.0034, 0.0169) 0.956
a: Parameter estimates with asymptotic standard deviations and empirical
standard deviations.
b: Intercept.
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B.2. Chapter 3
Figure B.1: Distribution of Breast Density Values in Phase II Controls.
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Table B.9: Estimates of AUC under Final Model in Real Data Analysis.
AUC 95% C.I.
MLE PL MLE PL
Lifelong 0.666 (0.011) 0.672 (0.013) (0.644, 0.688) (0.647, 0.697)
5 Year 0.659 (0.010) 0.666 (0.013) (0.639, 0.679) (0.641, 0.691)
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Table B.11: Observed and Estimated Breast Density Values in Phase II Controls.
Categorized Breast Density Value
0 1 2 3 4
Observed 224 590 461 293 48
Estimated by MLE method 208 625 478 259 46
Estimated by PL method 223 650 446 237 60
B.3. Chapter 4
B.4. Chapter 5
Table B.12: Joint and Conditional Distribution of Family Genotypes.
1 
 
Appendix 
Appendix Table 1: Joint and conditional distribution of family genotypes. 
G Gp Gc p(G, Gp, Gc) p(G | Gp, Gc) 
AA AA AA (1-pa)4 1-pa 
 Aa AA pa(1-pa)3 1-pa 
  Aa pa(1-pa)3 (1-pa)2 
 aa Aa pa2(1-pa)2 1-pa 
Aa AA AA pa(1-pa)3 pa 
  Aa pa(1-pa)3 1-pa 
 Aa AA pa2(1-pa)2 pa 
  Aa 2pa2(1-pa)2 2pa(1-pa) 
  aa pa2(1-pa)2 1-pa 
 aa Aa pa3(1-pa) pa 
  aa pa3(1-pa) 1-pa 
aa AA Aa pa2(1-pa)2 pa 
 Aa Aa pa3(1-pa) pa2 
  aa pa3(1-pa) pa 
 aa aa pa4 pa 
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Table B.13: Notational Glossary.
4 
 
Web Appendix Table 1: Notational glossary. 
N1 Number of cases, some living some deceased 
1
ˆ
j
N  Estimated number of cases with genotype j 
N0 Number of controls, all genotyped 
0
ˆ
j
N  Estimated number of controls with genotype j 
n1 Number of surviving cases 
m number of deceased cases (=N1-n1) 
nij Number with case status i and genotype j 
mjk Number of deceased cases with offspring genotype j and spouse genotype k 
mjc Number of deceased cases with offspring genotype j and no spouse genotype 
mjp Number of deceased cases with spouse genotype j 
mO Number of deceased cases with no offspring genotype information 
m1A, m1a 
Number of deceased case for whom we have a genotyped child and who must 
have passed allele A (a) to the child 
1 0 0 0 1 1 2 0 0 1 2A c
m m m m m m m

      ; 
1 1 0 2 1 2 2 2 1 0 2a c
m m m m m m m

       
m1Aa 
Number of deceased cases for whom we have a genotyped child and the child 
has genotype Aa 
1 1A a c
m m  
m1* 
Number of deceased cases whose family members’ genotypes provide no 
information in predicting cases’ genotype 
1* 1 1 O
m m m   
i j k
N  Number of subjects with case status i, genotype j, and environmental exposure k 
Y Disease status flag (1 if case) 
G Genotype of study participant 
G
f
, G
c
, G
p
 Genotype of deceased case’s family member(s) 
G
c
 Genotype of deceased case’s offspring 
G
p
 Genotype of deceased case’s spouse (the other parent of that offspring) 
S Survival status flag (1 if alive) 
R, R
c
, R
p
 
Flag for recruitability of family members, offspring and spouse for deceased case 
(1 if recruitable) 
121
5 
 
f(G) Function of G for logistic association with disease 
h(G) Function of G for logistic association with death, given disease 
β Genetic association parameter for disease association model 
ρ Proportion of deceased cases whose death is unrelated to G 
α Genetic association parameter for death model that conditions on disease 
pa MAF in the control population 
*
ˆ
a
p  Consistent estimator for the MAF in the case population 
**
ˆ
a
p  
Consistent estimator for the proportion of subjects with a allele in the case 
population 
γ Proportion of family members who are not recruitable. 
 
  
Table B.14: Multinomial Distribution for Families of Cases and Controls.
6 
 
Web Appendix Table 2: Multinomial distribution for families of cases and controls. 
G Gp Gc 
Probability for 
deceased cases 
Probability for 
surviving cases 
Probability for 
controls 
AA AA AA f(0)(1-q0) (1-pa)
4 f(0)q0 (1-pa)
4          (1-pa)
4 
 Aa AA f(0)(1-q0) pa(1-pa)
3 f(0)(q0) pa(1-pa)
3 pa(1-pa)
3 
  Aa f(0)(1-q0) pa(1-pa)
3 f(0)(q0) pa(1-pa)
3 pa(1-pa)
3 
 aa Aa f(0)(1-q0) pa
2(1-pa)
2 f(0)(q0) pa
2(1-pa)
2 pa
2(1-pa)
2 
Aa AA AA f(1)(1-q1) pa(1-pa)
3 f(1)(q1) pa(1-pa)
3 pa(1-pa)
3 
  Aa f(1)(1-q1) pa(1-pa)
3 f(1)(q1) pa(1-pa)
3 pa(1-pa)
3 
 Aa AA f(1)(1-q1) pa
2(1-pa)
2 f(1)(q1) pa
2(1-pa)
2 pa
2(1-pa)
2 
  Aa f(1)(1-q1) 2pa
2(1-pa)
2 f(1)(q1) 2pa
2(1-pa)
2 2pa
2(1-pa)
2 
  aa f(1)(1-q1) pa
2(1-pa)
2 f(1)(q1) pa
2(1-pa)
2  pa
2(1-pa)
2 
 aa Aa f(1)(1-q1) pa
3(1-pa) f(1)(q1) pa
3(1-pa) pa
3(1-pa) 
  aa f(1)(1-q1) pa
3(1-pa) f(1)(q1) pa
3(1-pa) pa
3(1-pa) 
aa AA Aa f(2)(1-q2) pa
2(1-pa)
2 f(2)(q2) pa
2(1-pa)
2         pa
2(1-pa)
2 
 Aa Aa f(2)(1-q2) pa
3(1-pa) f(2)(q2) pa
3(1-pa)  pa
3(1-pa) 
  aa f(2)(1-q2) pa
3(1-pa) f(2)(q2) pa
3(1-pa) pa
3(1-pa) 
 aa aa f(2)(1-q2) pa
4 f(2)(q2) pa
4 pa
4 
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Table B.15: Parameter Estimation and Power When Survival Model is Mis-specified
under Mixed Scenario for Genotyping Family Members of Deceased Cases.
3 
 
Web Appendix Table 3: Parameter Estimation and Power When Survival Model is Mis-specified 
under Mixed Scenario for Genotyping Family Members of Deceased Cases. 
Odds 
Ratio
a
 
γb 
True Survival Odds Ratio for G=2 
log(1) log(1.4) log(1.8) 
Est (S.D.) Power Est (S.D.) Power Est (S.D.) Power 
log(1) 
= 0 
1 -0.007 (0.143) 0.047 0.000 (0.143) 0.053 0.006 (0.144) 0.047 
0.7 -0.011 (0.169) 0.051 0.004 (0.169) 0.048 0.003 (0.169) 0.049 
0.5 -0.014 (0.197) 0.056 -0.002 (0.197) 0.057 0.004 (0.197) 0.055 
0
c
 -0.044 (0.148) 0.053 -0.046 (0.148) 0.054 -0.048 (0.148) 0.056 
log(1.4) 
= 0.336 
1 0.330 (0.142) 0.649 0.340 (0.143) 0.669 0.344 (0.143) 0.683 
0.7 0.332 (0.167) 0.507 0.336 (0.168) 0.512 0.339 (0.168) 0.520 
0.5 0.328 (0.194) 0.384 0.338 (0.195) 0.404 0.347 (0.195) 0.429 
0
c
 0.293 (0.144) 0.534 0.291 (0.144) 0.528 0.290 (0.144) 0.522 
log(1.8) 
= 0.588 
1 0.583 (0.144) 0.983 0.590 (0.145) 0.989 0.599 (0.145) 0.986 
0.7 0.576 (0.169) 0.936 0.589 (0.170) 0.945 0.600 (0.171) 0.950 
0.5 0.579 (0.197) 0.844 0.592 (0.197) 0.862 0.599 (0.198) 0.871 
0
c
 0.546 (0.143) 0.970 0.546 (0.143) 0.969 0.545 (0.143) 0.968 
a: The odds ratio of association.  
b: Recruiting probability for family members. 
*Sample size is 500 for cases and 500 for controls; ρ = 0.3, 
0
2   , and 1 1 .4e

 ; survival model is simulated as co-
dominant and analyzed as dominant. 
 
a: The odds ratio of assciation model.
b: Recruiting probability for family members.
c: The na¨ıve approach where no family members are recruited.
Sample size is 500 for cases and 500 for controls; ρ = 0.3, α0 = −2, and eα1 = 1.4
survival model is simulated as co-dominant and analyzed as dominant.
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Appendix Figures
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